|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [isoborneol results in decreased expression of ABCB1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:26593909 PMID:34915026 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [indolo(3,2-b)carbazole results in increased expression of ABCG2 mRNA] |
CTD |
PMID:17077187 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[Butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of ACE protein mutant form; [Butyrates co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased activity of ACE protein mutant form |
CTD |
PMID:20454656 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions decreases expression |
ISO |
ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein] |
CTD |
PMID:27638906 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in decreased stability of ACHE protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in increased degradation of ACHE protein] |
CTD |
PMID:22944069 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTA2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTB mRNA |
CTD |
PMID:15857753 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:113,877,763...113,883,356
Ensembl chr 2:113,877,763...113,884,029
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein]; 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein] |
CTD |
PMID:27638906 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Adss1 |
adenylosuccinate synthase 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ADSS1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr12:112,586,481...112,607,789
Ensembl chr12:112,586,479...112,607,794
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AGRP mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 8:106,293,327...106,306,477
Ensembl chr 8:106,293,330...106,364,025
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AGT protein results in increased degradation of SYP protein] |
CTD |
PMID:18487452 PMID:26612707 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions increases localization decreases expression affects localization increases expression |
ISO EXP |
AHR protein affects the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [beta-hexachlorocyclohexane affects the expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-formylindolo(3,2-b)carbazole results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AHR protein results in decreased expression of VIM protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate inhibits the reaction [AHR protein results in increased expression of ESR1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [herbimycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [monorden results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and affects the localization of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [AHR protein binds to VIM protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of AHR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of AHR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of and affects the localization of AHR protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of AHR protein MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:10497241 PMID:10722677 PMID:10922479 PMID:12002481 PMID:12237327 PMID:12606767 PMID:15385644 PMID:15899923 PMID:16891617 PMID:17445780 PMID:20057149 PMID:27752740 PMID:31676321 PMID:33207735 PMID:34801851 PMID:37217010 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B1 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413
|
|
G |
Akr1b10 |
aldo-keto reductase family 1, member B10 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B10 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [tolfenamic acid inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Cisplatin]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1C3 mRNA |
CTD |
PMID:21215737 PMID:23165153 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1c20 |
aldo-keto reductase family 1, member C20 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Salicylic Acid inhibits the reaction [AKR1C1 protein results in decreased susceptibility to Cisplatin]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1C1 mRNA |
CTD |
PMID:21215737 PMID:23165153 |
|
NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [cadmium acetate results in decreased expression of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in decreased phosphorylation of AKT1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKT1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of AKT1 protein AKT1 protein modified form inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [sodium arsenite affects the expression of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tubocapsenolide A results in increased degradation of AKT1 protein] |
CTD |
PMID:18442981 PMID:24085292 PMID:24449419 PMID:24933620 PMID:32061799 PMID:33256086 PMID:36807944 More...
|
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ANLN mRNA |
CTD |
PMID:25566086 PMID:31806706 |
|
NCBI chr 9:22,243,305...22,302,132
Ensembl chr 9:22,243,308...22,300,484
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ANXA2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of AOC3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:101,221,432...101,230,256
Ensembl chr11:101,221,431...101,232,764
|
|
G |
Aph1a |
aph1 homolog A, gamma secretase subunit |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:95,801,233...95,805,904
Ensembl chr 3:95,801,281...95,805,600
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [APP protein modified form results in decreased expression of and results in decreased activity of TERT protein] |
CTD |
PMID:21520056 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resiquimod results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr14:26,640,943...26,692,567
Ensembl chr14:26,640,945...26,693,189
|
|
G |
Aqp2 |
aquaporin 2 |
decreases degradation |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of AQP2 protein |
CTD |
PMID:21734099 |
|
NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428
|
|
G |
Aqp3 |
aquaporin 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP3 protein results in increased stability of EPAS1 protein]] |
CTD |
PMID:23545307 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP5 protein results in increased stability of EPAS1 protein]] |
CTD |
PMID:23545307 |
|
NCBI chr15:99,488,909...99,492,710
Ensembl chr15:99,488,663...99,492,710
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [decursin results in increased degradation of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [isobavachin results in decreased expression of and results in increased degradation of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulforaphane results in decreased expression of AR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Testosterone results in increased expression of AR mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of AR protein] |
CTD |
PMID:12376534 PMID:17723170 PMID:19805354 PMID:24740322 PMID:37019376 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Arg1 |
arginase, liver |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARIH1 protein 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARIH1 protein] |
CTD |
PMID:25624349 |
|
NCBI chr 9:59,295,837...59,395,469
Ensembl chr 9:59,295,541...59,393,901
|
|
G |
Arl6ip5 |
ADP-ribosylation factor-like 6 interacting protein 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]] |
CTD |
PMID:21600884 |
|
NCBI chr 6:97,187,753...97,210,276
Ensembl chr 6:97,187,650...97,210,276
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression multiple interactions decreases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARNT mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [SP1 protein binds to ARNT promoter]; bisindolylmaleimide I inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ARNT mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARNT protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in increased degradation of ARNT protein] |
CTD |
PMID:14529614 PMID:15899923 PMID:16880289 |
|
NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:92,479,659...92,562,487
Ensembl chr 5:92,479,686...92,562,487
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ASB2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:103,287,401...103,322,260
Ensembl chr12:103,287,401...103,322,260
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein] |
CTD |
PMID:23593480 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein] |
CTD |
PMID:14604972 PMID:17912641 PMID:23593480 PMID:31806706 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF6 protein 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF6 protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] |
CTD |
PMID:27638906 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of ATG12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:46,865,484...46,874,683
Ensembl chr18:46,863,211...46,874,647
|
|
G |
Atg13 |
autophagy related 13 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 2:91,504,957...91,540,947
Ensembl chr 2:91,504,963...91,540,921
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG7 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Atp13a2 |
ATPase type 13A2 |
decreases response to substance |
ISO |
ATP13A2 protein results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde analog |
CTD |
PMID:22847264 |
|
NCBI chr 4:140,711,812...140,734,641
Ensembl chr 4:140,714,184...140,734,641
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in decreased expression of ATP1A1 protein] |
CTD |
PMID:10506578 |
|
NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [troglitazone results in decreased expression of ATP5F1B mRNA] |
CTD |
PMID:20860658 |
|
NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
|
|
G |
Atp7b |
ATPase, Cu++ transporting, beta polypeptide |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of ATP7B protein |
CTD |
PMID:21189263 |
|
NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein] |
CTD |
PMID:24976383 |
|
NCBI chr 2:172,198,116...172,212,825
Ensembl chr 2:172,198,110...172,212,455
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein |
CTD |
PMID:24976383 |
|
NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490
|
|
G |
Bach1 |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
multiple interactions increases ubiquitination increases expression |
ISO |
2-tert-butylhydroquinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] affects the localization of BACH1 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of BACH1 protein; [Hemin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of BACH1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tetrachlorobenzoquinone results in increased degradation of BACH1 protein]; hydroquinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein]; quinone promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BACH1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BACH1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BACH1 protein |
CTD |
PMID:27393035 PMID:28645578 PMID:33434570 |
|
NCBI chr16:87,495,842...87,530,234
Ensembl chr16:87,495,833...87,530,234
|
|
G |
Bag3 |
BCL2-associated athanogene 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Staurosporine results in increased degradation of BAG3 protein] |
CTD |
PMID:19352495 |
|
NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of BAK1 protein |
CTD |
PMID:36346691 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of BAX protein MitoTEMPO inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BAX protein] |
CTD |
PMID:15782132 PMID:19540902 PMID:34418242 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcas2 |
BCAS2 pre-mRNA processing factor |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCAS2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:103,078,971...103,086,479
Ensembl chr 3:103,078,971...103,086,482
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased cleavage of BCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [trimethyltin chloride results in decreased expression of BCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein benzyloxycarbonyl-valyl-alanyl-aspartic acid promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein]; MitoTEMPO inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2 protein] |
CTD |
PMID:19540902 PMID:20005289 PMID:20100472 PMID:20449726 PMID:23423712 PMID:34418242 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of BCL2L1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BCL2L1 protein |
CTD |
PMID:16960866 PMID:19540902 PMID:19812371 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] |
CTD |
PMID:36509116 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC2 protein results in increased degradation of SOD1 protein mutant form] |
CTD |
PMID:27773815 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC3 protein results in increased degradation of SOD1 protein mutant form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BIRC3 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC3 protein |
CTD |
PMID:14527959 PMID:24085292 PMID:27773815 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BIRC5 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of BIRC5 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of BIRC5 mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with MK 2206] results in increased ubiquitination of BIRC5 protein; AKT1 protein modified form inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with dihydromyricetin] results in increased ubiquitination of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[pifithrin co-treated with Topotecan] results in increased degradation of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [dihydromyricetin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of BIRC5 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to [Oxaliplatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:16328441 PMID:17510429 PMID:17548900 PMID:19812371 PMID:19939880 PMID:20708607 PMID:23872705 PMID:25566086 PMID:36807944 More...
|
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BLVRB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:27,147,403...27,165,406
Ensembl chr 7:27,147,403...27,165,569
|
|
G |
Bmi1 |
Bmi1 polycomb ring finger oncogene |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BMI1 protein |
CTD |
PMID:33157086 |
|
NCBI chr 2:18,681,953...18,691,440
Ensembl chr 2:18,681,829...18,691,440
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of BNIP3 mRNA; arsenic trioxide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of BNIP3 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Valproic Acid results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25446377 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Bok |
BCL2-related ovarian killer |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of BOK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:93,613,297...93,623,492
Ensembl chr 1:93,613,382...93,623,486
|
|
G |
Brd4 |
bromodomain containing 4 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BRD4 mutant form affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [STA 9090 inhibits the reaction [PKD1 gene mutant form results in increased expression of BRD4 protein]] |
CTD |
PMID:23686307 PMID:25877301 PMID:26051217 |
|
NCBI chr17:32,415,246...32,503,717
Ensembl chr17:32,415,248...32,503,696
|
|
G |
C1qb |
complement component 1, q subcomponent, beta polypeptide |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of C1QB mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498
|
|
G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
decreases expression decreases degradation |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CACNA1H mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CACNA1H protein |
CTD |
PMID:25566086 PMID:30552955 |
|
NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of CANX protein |
CTD |
PMID:17912641 |
|
NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in increased expression of CAPN1 protein] |
CTD |
PMID:37353096 |
|
NCBI chr19:6,038,573...6,065,855
Ensembl chr19:6,038,573...6,065,927
|
|
G |
Car14 |
carbonic anhydrase 14 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:95,805,080...95,812,443
Ensembl chr 3:95,805,080...95,812,003
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]] |
CTD |
PMID:15914627 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased cleavage of CASP3 protein; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased activity of and results in increased cleavage of CASP3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CASP3 protein modified form |
CTD |
PMID:15498850 PMID:15725397 PMID:16880202 PMID:18463101 PMID:18790767 PMID:20005289 PMID:20100472 PMID:20449726 PMID:20649845 PMID:23684743 PMID:25449439 PMID:25568320 PMID:27638906 PMID:29944914 PMID:34418242 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp6 |
caspase 6 |
multiple interactions decreases activity |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of CASP6 protein |
CTD |
PMID:15914627 |
|
NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP7 protein |
CTD |
PMID:19139269 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP8 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP8 protein |
CTD |
PMID:15498850 PMID:15914627 PMID:20100472 PMID:20449726 PMID:20671745 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of and results in increased activity of CASP9 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CASP9 protein |
CTD |
PMID:15498850 PMID:16880202 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cast |
calpastatin |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in increased cleavage of CAST protein] |
CTD |
PMID:37353096 |
|
NCBI chr13:74,840,485...74,956,993
Ensembl chr13:74,840,487...74,956,929
|
|
G |
Cat |
catalase |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CAT mRNA CAT protein inhibits the reaction [[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein] |
CTD |
PMID:20061341 PMID:24973648 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
decreases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAV1 protein [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CAV1 mRNA |
CTD |
PMID:19706615 PMID:25566086 |
|
NCBI chr 6:17,306,387...17,341,323
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Cavin1 |
caveolae associated 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:100,847,562...100,861,443
Ensembl chr11:100,847,559...100,861,713
|
|
G |
Cavin2 |
caveolae associated 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:51,328,285...51,342,119
Ensembl chr 1:51,328,285...51,342,119
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA |
CTD |
PMID:20806931 |
|
NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCL2 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:10541287 PMID:11230753 PMID:11698246 PMID:15139008 PMID:19945525 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCL9 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:83,463,743...83,469,462
Ensembl chr11:83,463,745...83,469,462
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNA2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [arsenite results in increased ubiquitination of CCNB1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNB1 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17373649 PMID:20061341 PMID:25566086 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCNB2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases phosphorylation increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [3,3'-diindolylmethane analog results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alopestatin metabolite results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of CCND1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [kahweol results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lysocellin results in decreased expression of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel chloride results in decreased expression of and results in increased degradation of CCND1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel chloride results in decreased phosphorylation of CCND1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased degradation of CCND1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of CCND1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CCND1 protein |
CTD |
PMID:15247282 PMID:16051428 PMID:16525630 PMID:16707792 PMID:16965676 PMID:18792914 PMID:20394812 PMID:21472727 PMID:24231000 PMID:27424123 PMID:28548306 PMID:30703377 More...
|
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CCND3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Copper Sulfate co-treated with 2,3,2-tetramine] results in increased degradation of CCS protein] |
CTD |
PMID:12832419 |
|
NCBI chr19:4,875,394...4,889,326
Ensembl chr19:4,875,394...4,889,360
|
|
G |
Cd14 |
CD14 antigen |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851
|
|
G |
Cd1d1 |
CD1d1 antigen |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD1D1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:86,903,141...86,919,665
Ensembl chr 3:86,903,141...86,906,748
|
|
G |
Cd248 |
CD248 antigen, endosialin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CD248 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:5,118,106...5,120,668
Ensembl chr19:5,118,106...5,120,710
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD36 protein] |
CTD |
PMID:36534932 |
|
NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased degradation of CDC20 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC20 mRNA |
CTD |
PMID:20054826 PMID:20061341 PMID:25566086 |
|
NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549
|
|
G |
Cdc25b |
cell division cycle 25B |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC25B mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:131,028,356...131,040,431
Ensembl chr 2:131,028,869...131,040,417
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDC25C mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDCA3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 6:124,806,533...124,810,664
Ensembl chr 6:124,806,510...124,810,664
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDH3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:107,237,484...107,283,543
Ensembl chr 8:107,237,523...107,283,929
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDK1 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDK1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [troglitazone results in decreased expression of CDK2 protein] |
CTD |
PMID:15610522 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN2A mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Cdkn2c |
cyclin dependent kinase inhibitor 2C |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN2C mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:109,518,073...109,523,953
Ensembl chr 4:109,518,073...109,524,386
|
|
G |
Cdkn3 |
cyclin dependent kinase inhibitor 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CDKN3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr14:46,997,912...47,008,987
Ensembl chr14:46,997,998...47,009,126
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of CEBPA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] |
CTD |
PMID:19662097 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPB protein; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPB protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [N-acetylsphingosine results in decreased localization of CEBPB protein] |
CTD |
PMID:11779194 PMID:15319326 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPD protein; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased localization of CEBPD protein] |
CTD |
PMID:11779194 |
|
NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of CEBPE protein] |
CTD |
PMID:20945414 |
|
NCBI chr14:54,947,823...54,949,604
Ensembl chr14:54,947,817...54,949,631
|
|
G |
Cenpa |
centromere protein A |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:30,824,214...30,832,181
Ensembl chr 5:30,824,121...30,832,174
|
|
G |
Cers6 |
ceramide synthase 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 2:68,691,489...68,944,628
Ensembl chr 2:68,691,785...68,944,626
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of CFLAR protein alternative form benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound results in decreased expression of CFLAR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of CFLAR protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [shogaol results in decreased expression of CFLAR protein modified form] |
CTD |
PMID:16951203 PMID:17510429 PMID:18980244 PMID:25619640 PMID:26415225 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form] |
CTD |
PMID:18230692 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHEK1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2, cardiac |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHRM2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
increases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CHUK protein |
CTD |
PMID:24085292 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Cidea |
cell death-inducing DNA fragmentation factor, alpha subunit-like effector A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CIDEA mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:67,476,634...67,500,864
Ensembl chr18:67,476,674...67,500,855
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CITED4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:120,523,760...120,525,017
Ensembl chr 4:120,523,769...120,525,017
|
|
G |
Ckb |
creatine kinase, brain |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CKB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr13:92,001,510...92,025,001
Ensembl chr13:92,001,506...92,025,004
|
|
G |
Cldn4 |
claudin 4 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:134,973,977...134,975,788
Ensembl chr 5:134,973,973...134,975,788
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of and affects the localization of CLDN5 protein] |
CTD |
PMID:34391839 |
|
NCBI chr16:18,595,597...18,597,012
Ensembl chr16:18,595,597...18,597,012
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CLIP4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr17:72,076,674...72,171,205
Ensembl chr17:72,075,468...72,171,268
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CMYA5 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr13:93,177,221...93,281,278
Ensembl chr13:93,177,221...93,281,232
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA] |
CTD |
PMID:21525939 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA] |
CTD |
PMID:21525939 |
|
NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11306436 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Commd1 |
COMM domain containing 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of COMMD1 protein |
CTD |
PMID:23401744 |
|
NCBI chr11:22,849,728...22,934,539
Ensembl chr11:22,846,136...22,932,382
|
|
G |
Corin |
corin, serine peptidase |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:72,457,291...72,661,884
Ensembl chr 5:72,457,368...72,661,816
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4I2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of COX4I2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:152,596,093...152,606,957
Ensembl chr 2:152,596,093...152,606,957
|
|
G |
Cpxm1 |
carboxypeptidase X, M14 family member 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CPXM1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr 2:130,232,695...130,239,549
Ensembl chr 2:130,232,695...130,239,494
|
|
G |
Crct1 |
cysteine-rich C-terminal 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CRCT1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:92,921,512...92,922,993
Ensembl chr 3:92,921,512...92,922,994
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Valproic Acid results in decreased expression of CREBBP protein] |
CTD |
PMID:27381264 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crip2 |
cysteine rich protein 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRIP2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:113,103,856...113,109,126
Ensembl chr12:113,103,856...113,109,126
|
|
G |
Cryaa |
crystallin, alpha A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRYAA mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CRYAA protein |
CTD |
PMID:15914627 |
|
NCBI chr17:31,896,905...31,900,704
Ensembl chr17:31,896,781...31,900,707
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CRYAB mRNA |
CTD |
PMID:15914627 |
|
NCBI chr 9:50,657,251...50,667,936
Ensembl chr 9:50,662,625...50,667,936
|
|
G |
Csnk2b |
casein kinase 2, beta polypeptide |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate results in increased degradation of CSNK2B protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNFAIP1 protein results in increased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr17:35,335,171...35,341,029
Ensembl chr17:35,335,172...35,341,029
|
|
G |
Cst5 |
cystatin D |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CST5 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:149,247,242...149,252,217
Ensembl chr 2:149,246,977...149,252,213
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases degradation |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of CTNNB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arctigenin results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Aspirin results in increased ubiquitination of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in increased degradation of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [quinocetone results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RASSF5 protein results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Vitamin A results in decreased expression of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Nitroglycerin results in increased degradation of CTNNB1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of CTNNB1 protein; thymoquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of CTNNB1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the phosphorylation of and affects the localization of CTNNB1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of CTNNB1 protein; Phenobarbital inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CTNNB1 protein] |
CTD |
PMID:14555707 PMID:16878161 PMID:17030184 PMID:17219422 PMID:20510325 PMID:21472727 PMID:25217643 PMID:26990689 PMID:27693619 PMID:28343033 PMID:28548306 PMID:31115591 PMID:32112862 PMID:34900531 More...
|
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases cleavage |
ISO |
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein]; ATF6 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] |
CTD |
PMID:27638906 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
CUL2 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr18:3,382,970...3,436,700
Ensembl chr18:3,382,988...3,436,377
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA] |
CTD |
PMID:11698246 |
|
NCBI chr 8:95,498,808...95,509,055
Ensembl chr 8:95,498,637...95,509,055
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 protein] |
CTD |
PMID:11698246 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CXCL12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases secretion increases expression |
ISO |
Acetylcysteine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CXCL8 mRNA]; Antimycin A inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CXCL8 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chloroquine results in increased expression of CXCL8 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Titanium results in increased secretion of CXCL8 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; diphenyleneiodonium inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CXCL8 mRNA]; Glutathione inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CXCL8 mRNA]; Rotenone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CXCL8 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased secretion of CXCL8 protein |
CTD |
PMID:11698246 PMID:12208513 PMID:15139008 PMID:16392133 PMID:18457675 PMID:24085292 More...
|
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 protein] |
CTD |
PMID:11698246 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TPD7 compound results in decreased expression of CXCR4 protein] |
CTD |
PMID:25753200 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of CYCS protein |
CTD |
PMID:15725397 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Harmine results in decreased stability of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [harmol results in decreased stability of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of CYP1A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CYP1A1 protein |
CTD |
PMID:10722677 PMID:10777561 PMID:16093525 PMID:16891617 PMID:17606337 PMID:18835339 PMID:22001777 PMID:22037238 More...
|
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats |
RGD |
PMID:22079846 |
RGD:401794136 |
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of CYP1B1 protein |
CTD |
PMID:15486049 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CYP26A1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:24224465 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of DDC mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression increases activity |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DDIT3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of DDIT3 protein |
CTD |
PMID:17912641 PMID:19135031 PMID:19139269 PMID:22959925 PMID:23684743 PMID:25566086 PMID:27638906 More...
|
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Dffa |
DNA fragmentation factor, alpha subunit |
multiple interactions |
EXP |
DFFA protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DFFB protein] |
CTD |
PMID:18178165 |
|
NCBI chr 4:149,188,599...149,205,110
Ensembl chr 4:149,188,603...149,205,104
|
|
G |
Dffb |
DNA fragmentation factor, beta subunit |
multiple interactions increases ubiquitination decreases degradation |
EXP |
DFFA protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DFFB protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of DFFB protein |
CTD |
PMID:18178165 |
|
NCBI chr 4:154,048,904...154,059,578
Ensembl chr 4:154,048,906...154,059,583
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]] |
CTD |
PMID:31699976 |
|
NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
|
|
G |
Dio2 |
deiodinase, iodothyronine, type II |
multiple interactions increases activity increases expression |
ISO |
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [decabromobiphenyl ether results in increased degradation of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased activity of DIO2 protein; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of DIO2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DIO2 protein |
CTD |
PMID:11425850 PMID:17615150 PMID:26004626 PMID:37330034 |
|
NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJB1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJB1 protein |
CTD |
PMID:15525353 PMID:25566086 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajc2 |
DnaJ heat shock protein family (Hsp40) member C2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNAJC2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:21,962,279...21,990,183
Ensembl chr 5:21,962,265...21,990,249
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
multiple interactions increases ubiquitination |
EXP |
1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [DNAJC7 protein results in increased expression of NR1I3 protein]; NR1I3 protein affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]] |
CTD |
PMID:24789201 |
|
NCBI chr11:100,473,644...100,511,030
Ensembl chr11:100,473,644...100,511,014
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Benzo(a)pyrene results in increased degradation of DNMT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [quinoline analog results in increased degradation of DNMT1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT1 protein] |
CTD |
PMID:19417133 PMID:21150308 PMID:23395981 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT3A protein] |
CTD |
PMID:23395981 |
|
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of DNMT3B protein] |
CTD |
PMID:23395981 |
|
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
Dnmt3l |
DNA methyltransferase 3-like |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNMT3L mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:77,878,121...77,899,456
Ensembl chr10:77,877,781...77,899,456
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 2:25,242,302...25,246,365
Ensembl chr 2:25,242,288...25,246,371
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SKP2 protein results in decreased expression of DUSP1 protein] |
CTD |
PMID:34697729 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Dync1h1 |
dynein cytoplasmic 1 heavy chain 1 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr12:110,567,829...110,633,378
Ensembl chr12:110,567,886...110,633,379
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dronabinol results in decreased expression of E2F1 protein] |
CTD |
PMID:17934890 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
E2f2 |
E2F transcription factor 2 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of E2F2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 4:135,899,585...135,923,368
Ensembl chr 4:135,899,705...135,923,368
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EDN1 mRNA |
CTD |
PMID:18457675 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EGF mRNA |
CTD |
PMID:22689575 PMID:22766066 PMID:31806706 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfl7 |
EGF-like domain 7 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of EGFL7 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:26,471,095...26,482,694
Ensembl chr 2:26,470,026...26,483,132
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGFR protein |
CTD |
PMID:17146438 PMID:20332299 PMID:22457794 PMID:28711525 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr12:54,225,767...54,250,660
Ensembl chr12:54,225,767...54,250,646
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of EIF2AK2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:79,157,933...79,190,001
Ensembl chr17:79,159,993...79,190,002
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:22959925 PMID:27638906 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EIF2S1 protein modified form 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein]; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of EIF2S1 protein]; PTPN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:21090173 PMID:22321511 PMID:23684743 PMID:25568320 PMID:27638906 PMID:28359145 More...
|
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in decreased expression of EIF4E protein] |
CTD |
PMID:15878868 |
|
NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ELAVL1 protein |
CTD |
PMID:23922739 |
|
NCBI chr 8:4,334,781...4,375,104
Ensembl chr 8:4,335,382...4,375,413
|
|
G |
Emcn |
endomucin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EMCN mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:137,046,824...137,136,830
Ensembl chr 3:137,046,828...137,137,946
|
|
G |
Eno3 |
enolase 3, beta muscle |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin affects the localization of EP300 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased degradation of EP300 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SIRT6 protein results in decreased expression of EP300 protein] |
CTD |
PMID:15767673 PMID:17927689 PMID:27094368 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions increases stability increases hydroxylation increases expression increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP3 protein results in increased stability of EPAS1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen inhibits the reaction [AQP5 protein results in increased stability of EPAS1 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of EPAS1 protein [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; [Formaldehyde co-treated with VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; [VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein; arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of EPAS1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [MALAT1 mRNA promotes the reaction [sodium arsenite results in increased expression of EPAS1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]; MALAT1 mRNA promotes the reaction [sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]]; sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPAS1 protein |
CTD |
PMID:22447124 PMID:23545307 PMID:26735578 PMID:35504338 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Ephb4 |
Eph receptor B4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Homoharringtonine results in decreased expression of EPHB4 protein] |
CTD |
PMID:31726078 |
|
NCBI chr 5:137,348,371...137,372,784
Ensembl chr 5:137,348,371...137,376,931
|
|
G |
Ephx1 |
epoxide hydrolase 1, microsomal |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPHX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469
|
|
G |
Ephx2 |
epoxide hydrolase 2, cytoplasmic |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPHX2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr14:66,321,821...66,361,971
Ensembl chr14:66,321,823...66,361,949
|
|
G |
Epo |
erythropoietin |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of EPO protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of EPO protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of EPO protein |
CTD |
PMID:31850806 PMID:32461003 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Eppk1 |
epiplakin 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EPPK1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:75,973,337...76,004,395
Ensembl chr15:75,973,330...76,004,395
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [demethoxycurcumin results in increased degradation of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein] |
CTD |
PMID:18655187 PMID:20332299 PMID:31806706 PMID:33325633 PMID:34291863 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of ERBB3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB3 protein |
CTD |
PMID:20332299 |
|
NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ERCC6 gene mutant form results in decreased expression of SIRT1 protein] |
CTD |
PMID:25440059 |
|
NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
increases expression multiple interactions increases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ERN1 protein ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACE2 protein]; ERN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of CTSD protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of ERN1 protein |
CTD |
PMID:19139269 PMID:27638906 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions increases expression decreases expression increases ubiquitination |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [baohuoside I results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Butyrophenones results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of ESR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Carbamazepine results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate inhibits the reaction [AHR protein results in increased expression of ESR1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol inhibits the reaction [ESR1 protein binds to GSK3B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Fulvestrant results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Okadaic Acid results in increased degradation of ESR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Plant Extracts results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [xanthohumol results in decreased expression of ESR1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [PTK2B protein affects the ubiquitination of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gonadotropin-Releasing Hormone results in decreased expression of ESR1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESR1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [fulvestrant results in increased degradation of ESR1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ESR1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of ESR1 protein |
CTD |
PMID:12612060 PMID:14702340 PMID:14750165 PMID:15965230 PMID:16055746 PMID:16965676 PMID:20419096 PMID:21041310 PMID:26990689 PMID:29428397 PMID:31806706 PMID:32986415 PMID:34801851 PMID:35802278 More...
|
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESR2 protein |
CTD |
PMID:14702340 PMID:15207704 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HDAC6 protein results in increased expression of ESRRA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ESRRA protein |
CTD |
PMID:34524571 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Fahd1 |
fumarylacetoacetate hydrolase domain containing 1 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of FAHD1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:25,067,866...25,069,276
Ensembl chr17:25,067,866...25,069,338
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of FAM13B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:34,573,624...34,656,096
Ensembl chr18:34,575,404...34,639,884
|
|
G |
Fam78a |
family with sequence similarity 78, member A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FAM78A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:31,932,720...31,977,484
Ensembl chr 2:31,940,098...31,954,923 Ensembl chr 2:31,940,098...31,954,923
|
|
G |
Fasl |
Fas ligand |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased expression of FASLG protein] |
CTD |
PMID:20005289 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fbxl12 |
F-box and leucine-rich repeat protein 12 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXL12 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 9:20,549,045...20,556,064
Ensembl chr 9:20,529,414...20,556,063
|
|
G |
Fbxo10 |
F-box protein 10 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXO10 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:45,034,248...45,084,555
Ensembl chr 4:45,034,247...45,084,604
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FBXO2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:148,244,605...148,250,874
Ensembl chr 4:148,245,078...148,250,881
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [FBXO32 protein results in decreased expression of KCNN2 protein] |
CTD |
PMID:30635400 |
|
NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328
|
|
G |
Fbxo6 |
F-box protein 6 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FBXO6 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:148,230,173...148,236,592
Ensembl chr 4:148,230,173...148,236,597
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
multiple interactions |
EXP |
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]] |
CTD |
PMID:24457827 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FHL2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FIS1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[ponasterone A results in increased expression of PINK1 protein] which results in decreased expression of FIS1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[PARK protein co-treated with UBB protein] results in decreased expression of FIS1 protein] |
CTD |
PMID:20164189 |
|
NCBI chr 5:136,982,129...136,995,088
Ensembl chr 5:136,982,129...136,995,088
|
|
G |
Flnc |
filamin C, gamma |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FLNC mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882
|
|
G |
Fn1 |
fibronectin 1 |
decreases secretion |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased secretion of FN1 protein |
CTD |
PMID:11594554 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hydrogen Peroxide results in increased expression of FOS protein] [Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein |
CTD |
PMID:15136564 PMID:20551291 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosl1 |
fos-like antigen 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL1 protein]] |
CTD |
PMID:17148446 |
|
NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FOXM1 mRNA |
CTD |
PMID:22094256 PMID:31806706 |
|
NCBI chr 6:128,339,957...128,352,849
Ensembl chr 6:128,339,930...128,353,109
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [dorsomorphin results in decreased expression of FOXO1 protein] |
CTD |
PMID:25065674 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in increased expression of FOXO3 protein] |
CTD |
PMID:31421153 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FSD2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:81,184,102...81,216,729
Ensembl chr 7:81,183,056...81,216,692
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diallyl trisulfide results in increased degradation of and results in decreased expression of FTH1 protein] |
CTD |
PMID:16707465 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diallyl trisulfide results in increased degradation of and results in decreased expression of FTL protein] |
CTD |
PMID:16707465 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Rotenone] results in increased expression of FUNDC1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Rotenone results in decreased expression of FUNDC1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of FUNDC1 protein |
CTD |
PMID:32001317 PMID:37156403 |
|
NCBI chr X:17,386,206...17,438,600
Ensembl chr X:17,422,803...17,438,564
|
|
G |
G0s2 |
G0/G1 switch gene 2 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of G0S2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:192,954,468...192,955,496
Ensembl chr 1:192,954,469...192,955,525
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 6:129,510,155...129,519,294
Ensembl chr 6:129,510,123...129,519,309
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction and affects the localization of [PSMC5 protein binds to GABBR2 protein] |
CTD |
PMID:24482233 |
|
NCBI chr 4:46,662,318...46,991,714
Ensembl chr 4:46,662,305...46,991,873
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen deficiency results in decreased expression of GAD1 protein] |
CTD |
PMID:29107683 |
|
NCBI chr 2:70,392,109...70,432,358
Ensembl chr 2:70,383,416...70,432,358
|
|
G |
Gad2 |
glutamic acid decarboxylase 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen deficiency results in decreased expression of GAD2 protein] |
CTD |
PMID:29107683 |
|
NCBI chr 2:22,512,262...22,583,889
Ensembl chr 2:22,512,217...22,583,886
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GADD45A mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible 45 gamma |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of GADD45G mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of GCLC mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of GCLC protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC protein |
CTD |
PMID:25263748 PMID:30186748 PMID:33434570 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GCLM protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLM protein |
CTD |
PMID:20061341 PMID:33434570 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GDF15 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [antofine results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ioxynil analog results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ioxynil results in decreased expression of GJA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of GJA1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [fulvestrant results in decreased expression of GJA1 protein] |
CTD |
PMID:15685554 PMID:20510257 PMID:23403203 PMID:29180066 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GJA5 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:96,939,718...96,960,950
Ensembl chr 3:96,812,009...96,984,732
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diphenylarsinic acid results in increased degradation of GLS protein alternative form] |
CTD |
PMID:22493432 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of GPR146 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:139,363,452...139,382,170
Ensembl chr 5:139,363,452...139,382,170
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression decreases expression |
ISO |
[sodium arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of GPX1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of GPX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in decreased expression of GPX1 mRNA]; sodium arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GPX1 protein]; sodium arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GPX1 mRNA] |
CTD |
PMID:32301004 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gria1 |
glutamate receptor, ionotropic, AMPA1 (alpha 1) |
increases localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of GRIA1 protein |
CTD |
PMID:19674091 |
|
NCBI chr11:56,902,342...57,221,070
Ensembl chr11:56,902,213...57,221,070
|
|
G |
Gria2 |
glutamate receptor, ionotropic, AMPA2 (alpha 2) |
increases localization |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of GRIA2 protein |
CTD |
PMID:19674091 |
|
NCBI chr 3:80,588,757...80,711,534
Ensembl chr 3:80,588,757...80,710,142
|
|
G |
Grip1 |
glutamate receptor interacting protein 1 |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GRIP1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GRIP1 protein binds to NR1I3 protein] |
CTD |
PMID:24224465 PMID:25566086 |
|
NCBI chr10:119,289,810...119,923,172
Ensembl chr10:119,289,735...119,923,166
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of and results in increased cleavage of GSDMD protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of GSDMD protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of and results in increased cleavage of GSDMD protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of GSDMD protein] |
CTD |
PMID:34920032 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Gsg1l |
GSG1-like |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSG1L mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:125,477,584...125,681,929
Ensembl chr 7:125,477,592...125,681,583
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases expression increases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Estradiol inhibits the reaction [ESR1 protein binds to GSK3B protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSK3B protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of GSK3B protein |
CTD |
PMID:24085292 PMID:26990689 PMID:30703377 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gsr |
glutathione reductase |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSR protein |
CTD |
PMID:20061341 PMID:33434570 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gss |
glutathione synthetase |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSS mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:155,405,101...155,434,730
Ensembl chr 2:155,405,101...155,434,730
|
|
G |
Gsta1 |
glutathione S-transferase, alpha 1 (Ya) |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]] |
CTD |
PMID:16243960 |
|
NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966
|
|
G |
Gsta2 |
glutathione S-transferase, alpha 2 (Yc2) |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTA2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070
|
|
G |
Gsta3 |
glutathione S-transferase, alpha 3 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTA3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 1:21,310,837...21,335,885
Ensembl chr 1:21,310,813...21,335,885
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM5 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTM3 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTO1 mRNA [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of GSTO1 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr19:47,843,412...47,853,229
Ensembl chr19:47,843,409...47,853,229
|
|
G |
Gsto2 |
glutathione S-transferase omega 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTO2 mRNA |
CTD |
PMID:33434570 |
|
NCBI chr19:47,853,879...47,874,747
Ensembl chr19:47,853,973...47,874,763
|
|
G |
Gstp1 |
glutathione S-transferase, pi 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GSTP1 protein |
CTD |
PMID:15863507 |
|
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
|
|
G |
Gucy1a1 |
guanylate cyclase 1, soluble, alpha 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:81,999,734...82,053,253
Ensembl chr 3:81,999,734...82,053,096
|
|
G |
Gyg1 |
glycogenin 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GYG1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GYG1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:20,176,248...20,209,228
Ensembl chr 3:20,176,248...20,209,481
|
|
G |
H19 |
H19, imprinted maternally expressed transcript |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H19 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:142,129,267...142,131,883
Ensembl chr 7:142,129,262...142,131,917
|
|
G |
H2-Ab1 |
histocompatibility 2, class II antigen A, beta 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H2-AB1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr17:34,482,201...34,488,392
Ensembl chr17:34,476,663...34,488,393
|
|
G |
H2ac10 |
H2A clustered histone 10 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC10 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:23,718,045...23,718,548
Ensembl chr13:23,718,076...23,718,474
|
|
G |
H2ac12 |
H2A clustered histone 12 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC12 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:22,219,292...22,219,813
Ensembl chr13:22,219,334...22,219,738
|
|
G |
H2ac13 |
H2A clustered histone 13 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC13 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:21,900,582...21,901,029
Ensembl chr13:21,900,592...21,900,984
|
|
G |
H2ac22 |
H2A clustered histone 22 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC22 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:21,970,944...21,971,418
Ensembl chr13:21,970,996...21,971,388
|
|
G |
H2ac6 |
H2A clustered histone 6 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC15 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:23,867,456...23,867,942
Ensembl chr13:23,865,450...23,867,931
|
|
G |
H2ac7 |
H2A clustered histone 7 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC7 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:23,758,555...23,759,089
Ensembl chr13:23,758,555...23,759,126
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:17875725 PMID:21227924 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
H4c16 |
H4 histone 16 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Progesterone results in increased acetylation of H4C16 protein] |
CTD |
PMID:15857753 |
|
NCBI chr 6:136,780,991...136,781,429
Ensembl chr 6:136,778,551...136,781,413
|
|
G |
Haghl |
hydroxyacylglutathione hydrolase-like |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HAGHL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:25,998,817...26,004,560
Ensembl chr17:25,998,817...26,004,647
|
|
G |
Hax1 |
HCLS1 associated X-1 |
affects expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of HAX1 protein |
CTD |
PMID:19763263 |
|
NCBI chr 3:89,902,753...89,906,023
Ensembl chr 3:89,902,753...89,906,087
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin affects the localization of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of HDAC1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Particulate Matter results in increased degradation of HDAC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Vehicle Emissions results in increased degradation of HDAC1 protein] |
CTD |
PMID:17395887 PMID:17927689 |
|
NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
|
|
G |
Hdac2 |
histone deacetylase 2 |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HDAC2 protein [SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Smoke results in increased degradation of and results in decreased expression of HDAC2 protein]; CAT protein inhibits the reaction [[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein] |
CTD |
PMID:18421014 PMID:24973648 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HDAC6 protein results in increased expression of ESRRA protein] |
CTD |
PMID:34524571 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HES1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
decreases degradation increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of HIF1A protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of HIF1A protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein] 3-(4-bromophenyl)-2-(ethylsulfonyl)-6-methylquinoxaline-1,4-dioxide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; [andrographolide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HIF1A protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; [Formaldehyde co-treated with VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; [Oxygen deficiency co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the expression of HIF1A protein; [VH298 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [geldanamycin results in increased degradation of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [L-4F peptide inhibits the reaction [INS protein results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MALAT1 mRNA affects the reaction [sodium arsenite results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [scutellarin results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VHL protein binds to HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of HIF1A protein; bruceine D inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Curcumin analog inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Curcumin analog inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein modified form]; diallyl trisulfide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of HIF1A protein]; dictamnine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Digitoxin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; dihydrotanshinone I inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the expression of HIF1A protein]; Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]]; Resveratrol inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of HIF1A protein] |
CTD |
PMID:11980636 PMID:17764071 PMID:17973296 PMID:18682687 PMID:19254699 PMID:19263519 PMID:20335389 PMID:20524035 PMID:20554536 PMID:21134392 PMID:22537771 PMID:23593480 PMID:24221993 PMID:24497960 PMID:24975222 PMID:25192544 PMID:26282490 PMID:27287256 PMID:28574600 PMID:28651835 PMID:29630948 PMID:30266538 PMID:31850806 PMID:32461003 PMID:34717917 PMID:34900531 PMID:35504338 PMID:35513012 More...
|
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Higd1b |
HIG1 domain family, member 1B |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:102,726,597...102,728,866
Ensembl chr11:102,726,675...102,728,866
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [cobaltous chloride results in decreased expression of HIPK2 protein] |
CTD |
PMID:19714248 |
|
NCBI chr 6:38,664,447...38,853,236
Ensembl chr 6:38,671,325...38,853,099
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions increases ubiquitination |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HMOX1 mRNA] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of HMOX1 protein; [USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; [USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; Arsenic inhibits the reaction [[USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [[USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]; HMOX1 protein inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA]; USP7 protein affects the reaction [Arsenic inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein]]; USP7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein] |
CTD |
PMID:12441344 PMID:18550526 PMID:18835339 PMID:25824035 PMID:30186748 PMID:33434570 PMID:35821281 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetracaine results in decreased expression of HNRNPA1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Thapsigargin affects the localization of HNRNPA1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tunicamycin affects the localization of HNRNPA1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:23106379 PMID:34822839 |
|
NCBI chr15:103,148,840...103,155,119
Ensembl chr15:103,148,859...103,155,119
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NSC606985 results in decreased expression of HNRNPK protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [PRKCD protein results in increased ubiquitination of HNRNPK protein] |
CTD |
PMID:19747914 |
|
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
|
|
G |
Hopx |
HOP homeobox |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HOPX mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:77,234,831...77,262,970
Ensembl chr 5:77,234,835...77,262,968
|
|
G |
Hp |
haptoglobin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HP mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804
|
|
G |
Hr |
lysine demethylase and nuclear receptor corepressor |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HR mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:70,789,644...70,810,988
Ensembl chr14:70,789,652...70,810,988
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Progesterone results in increased expression of HSD11B2 mRNA] |
CTD |
PMID:15857753 |
|
NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620
|
|
G |
Hsf1 |
heat shock factor 1 |
increases activity multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of HSF1 protein HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 mRNA]; HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UBC mRNA] |
CTD |
PMID:11893605 PMID:30186748 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Hsf2 |
heat shock factor 2 |
increases activity multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of HSF2 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF2 protein] |
CTD |
PMID:11893605 PMID:15914627 |
|
NCBI chr10:57,359,862...57,389,239
Ensembl chr10:57,362,481...57,389,231
|
|
G |
Hsf4 |
heat shock transcription factor 4 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF4 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSF4 protein] |
CTD |
PMID:15914627 |
|
NCBI chr 8:105,996,392...106,002,477
Ensembl chr 8:105,996,433...106,002,477
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hspa1a |
heat shock protein 1A |
multiple interactions increases expression |
ISO EXP |
PARK7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A mRNA |
CTD |
PMID:18331584 PMID:25566086 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa1b |
heat shock protein 1B |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1B mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1B protein |
CTD |
PMID:15525353 PMID:25566086 |
|
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
|
|
G |
Hspa4 |
heat shock protein 4 |
multiple interactions increases expression |
EXP ISO |
Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 protein] HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA4 mRNA] |
CTD |
PMID:15914627 PMID:30186748 |
|
NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA5 protein |
CTD |
PMID:19139269 PMID:21692457 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of HSPA8 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hspa9 |
heat shock protein 9 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in decreased expression of HSPA9 protein] |
CTD |
PMID:37353096 |
|
NCBI chr18:35,070,467...35,087,404
Ensembl chr18:35,070,467...35,087,410
|
|
G |
Hspb1 |
heat shock protein 1 |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPB1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [bufalin results in decreased expression of HSPB1 protein] |
CTD |
PMID:15914627 PMID:23091618 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspb2 |
heat shock protein 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:50,662,372...50,663,654
Ensembl chr 9:50,662,378...50,663,654
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPH1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HTRA2 protein |
CTD |
PMID:19763263 |
|
NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] MG132 pretreatment decreases expression of protein in liver of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11698246 PMID:14572618 PMID:22079846 |
RGD:401794136 |
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP1 protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP6 protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IFNG protein results in increased activity of CASP8 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]] |
CTD |
PMID:15914627 PMID:19393675 PMID:23395999 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [platycodin D results in decreased expression of IGF1R protein] |
CTD |
PMID:28711525 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Isoproterenol results in increased secretion of IL18 protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of IL18 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL18 protein] |
CTD |
PMID:15178407 PMID:34920032 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of IL1A mRNA |
CTD |
PMID:11230753 PMID:15728660 PMID:20061341 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases response to substance |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of IL1B protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL1B protein]; sodium arsenite inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to IL1B protein |
CTD |
PMID:10541287 PMID:11835394 PMID:14581482 PMID:19393675 PMID:23395999 PMID:34920032 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 protein Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 mRNA]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IL6 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] MG132 pretreatment decreases expression of TNFa, IL6 protein in serum of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11893605 PMID:18457675 PMID:28134560 PMID:31806706 PMID:22079846 |
RGD:401794136 |
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Impact |
impact, RWD domain protein |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IMPACT mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:13,087,747...13,126,007
Ensembl chr18:13,088,909...13,126,007
|
|
G |
Inafm2 |
InaF motif containing 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of INAFM2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:118,576,239...118,579,291
Ensembl chr 2:118,576,239...118,579,291
|
|
G |
Ins1 |
insulin I |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [INS1 protein results in decreased expression of IRS1 protein] |
CTD |
PMID:24219910 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [L-4F peptide inhibits the reaction [INS protein results in increased expression of HIF1A protein]] |
CTD |
PMID:22537771 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Insl6 |
insulin-like 6 |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of INSL6 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr19:29,298,754...29,302,718
Ensembl chr19:29,298,744...29,302,756
|
|
G |
Irf8 |
interferon regulatory factor 8 |
decreases degradation |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of IRF8 protein |
CTD |
PMID:15837792 |
|
NCBI chr 8:121,463,097...121,483,433
Ensembl chr 8:121,463,097...121,483,433
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [INS1 protein results in decreased expression of IRS1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in decreased expression of IRS1 protein] |
CTD |
PMID:24219910 PMID:32061799 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Irx3 |
Iroquois related homeobox 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of IRX3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:92,525,139...92,528,282
Ensembl chr 8:92,525,153...92,528,695
|
|
G |
Itgam |
integrin alpha M |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:20945414 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgb1bp2 |
integrin beta 1 binding protein 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ITGB1BP2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr X:100,492,694...100,520,391
Ensembl chr X:100,492,694...100,497,147
|
|
G |
Itpr3 |
inositol 1,4,5-triphosphate receptor 3 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acrylamide results in decreased expression of ITPR3 protein] |
CTD |
PMID:37353096 |
|
NCBI chr17:27,275,976...27,341,197
Ensembl chr17:27,276,278...27,341,197
|
|
G |
Ivl |
involucrin |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of IVL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:92,478,206...92,481,097
Ensembl chr 3:92,478,209...92,481,042
|
|
G |
Jun |
jun proto-oncogene |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KU-32 compound inhibits the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] |
CTD |
PMID:23240583 PMID:23593480 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of JUNB protein]] |
CTD |
PMID:17148446 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Kat5 |
K(lysine) acetyltransferase 5 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KAT5 protein results in increased acetylation of and results in increased degradation of SRSF2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of KAT5 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KAT5 protein |
CTD |
PMID:21157427 PMID:28837777 |
|
NCBI chr19:5,653,042...5,661,584
Ensembl chr19:5,653,042...5,660,265
|
|
G |
Katnb1 |
katanin p80 (WD40-containing) subunit B 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KATNB1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:95,807,804...95,826,502
Ensembl chr 8:95,807,814...95,829,777
|
|
G |
Kbtbd11 |
kelch repeat and BTB (POZ) domain containing 11 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:15,059,408...15,083,333
Ensembl chr 8:15,061,025...15,083,333
|
|
G |
Kcng2 |
potassium voltage-gated channel, subfamily G, member 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KCNG2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:80,337,731...80,407,469
Ensembl chr18:80,337,761...80,407,469
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide results in increased degradation of KCNH2 protein] |
CTD |
PMID:28521025 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnip3 |
Kv channel interacting protein 3, calsenilin |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein] |
CTD |
PMID:30503815 |
|
NCBI chr 2:127,298,418...127,364,014
Ensembl chr 2:127,298,418...127,364,014
|
|
G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [FBXO32 protein results in decreased expression of KCNN2 protein] |
CTD |
PMID:30635400 |
|
NCBI chr18:45,401,754...45,818,954
Ensembl chr18:45,401,927...45,818,950
|
|
G |
Kdm1a |
lysine (K)-specific demethylase 1A |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SP2509 results in decreased stability of KDM1A protein] |
CTD |
PMID:29581250 |
|
NCBI chr 4:136,277,844...136,330,127
Ensembl chr 4:136,277,851...136,330,034
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
[2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to KEAP1 protein] |
CTD |
PMID:18512965 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:92,943,180...93,029,760
Ensembl chr 1:92,943,186...93,029,673
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:149,260,776...149,392,762
Ensembl chr 4:149,260,776...149,392,150
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KIF20A mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:34,757,677...34,766,330
Ensembl chr18:34,757,666...34,766,330
|
|
G |
Kif4 |
kinesin family member 4 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KIF4 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr X:99,669,693...99,770,878
Ensembl chr X:99,669,343...99,770,820
|
|
G |
Klf2 |
Kruppel-like transcription factor 2 (lung) |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TRAF2 protein results in decreased expression of KLF2 protein] |
CTD |
PMID:35635602 |
|
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
|
|
G |
Klf6 |
Kruppel-like transcription factor 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KLF6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
|
|
G |
Klhl6 |
kelch-like 6 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KLHL6 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr16:19,765,242...19,801,766
Ensembl chr16:19,765,246...19,801,787
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KNSTRN mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:118,644,470...118,667,691
Ensembl chr 2:118,644,484...118,684,438
|
|
G |
Kras |
Kirsten rat sarcoma viral oncogene homolog |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KRAS mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [Diacetyl affects the expression of and affects the ubiquitination of KRT5 protein] |
CTD |
PMID:32112875 |
|
NCBI chr15:101,615,504...101,621,340
Ensembl chr15:101,615,505...101,621,333
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KY mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:102,382,954...102,423,443
Ensembl chr 9:102,382,949...102,423,438
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [10-(octyloxy)decyl-2-(trimethylammonium)ethyl phosphate results in decreased expression of LAT2 protein] |
CTD |
PMID:23001822 |
|
NCBI chr 5:134,628,957...134,648,637
Ensembl chr 5:134,628,876...134,643,879
|
|
G |
Ldb3 |
LIM domain binding 3 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LDB3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:34,248,656...34,312,276
Ensembl chr14:34,248,560...34,310,639
|
|
G |
Lgals1 |
lectin, galactose binding, soluble 1 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:78,810,925...78,814,665
Ensembl chr15:78,810,925...78,814,665
|
|
G |
Lmo7 |
LIM domain only 7 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LMO7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr14:101,967,353...102,172,144
Ensembl chr14:101,967,386...102,172,146
|
|
G |
Lnx1 |
ligand of numb-protein X 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LNX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:74,753,108...74,865,203
Ensembl chr 5:74,753,108...74,863,573
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TGFB1 protein results in decreased expression of LPIN1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of LPIN1 protein |
CTD |
PMID:27345520 |
|
NCBI chr12:16,585,670...16,697,020
Ensembl chr12:16,585,670...16,696,967
|
|
G |
Lrrc10 |
leucine rich repeat containing 10 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC10 mRNA; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:116,881,246...116,882,673
Ensembl chr10:116,881,246...116,882,673
|
|
G |
Lrrc75a |
leucine rich repeat containing 75A |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC75A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:62,495,708...62,539,411
Ensembl chr11:62,495,710...62,539,349
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of LRRK2 protein |
CTD |
PMID:24942733 |
|
NCBI chr15:91,556,994...91,700,327
Ensembl chr15:91,557,378...91,700,323
|
|
G |
Luc7l |
Luc7-like |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of LUC7L mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:26,471,874...26,504,484
Ensembl chr17:26,471,870...26,504,478
|
|
G |
Lxn |
latexin |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:67,365,332...67,371,240
Ensembl chr 3:67,365,331...67,371,259
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of and results in decreased degradation of MAF1 protein; CUL2 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr15:76,235,494...76,238,578
Ensembl chr15:76,235,494...76,238,580
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MALAT1 mRNA affects the reaction [sodium arsenite results in increased expression of HIF1A protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [MALAT1 mRNA promotes the reaction [sodium arsenite results in increased expression of EPAS1 protein]]; MALAT1 mRNA promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]; MALAT1 mRNA promotes the reaction [sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased hydroxylation of EPAS1 protein]] |
CTD |
PMID:26735578 PMID:27287256 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,852,706
|
|
G |
Map1b |
microtubule-associated protein 1B |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr13:99,557,972...99,653,110
Ensembl chr13:99,557,954...99,653,048
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1LC3B protein modified form benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trovafloxacin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; MAP1LC3B protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24085292 PMID:26409479 PMID:33609687 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions decreases response to substance |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of MAPK8 protein MAPK8 affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] MAPK8 gene mutant form results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde |
CTD |
PMID:18463101 PMID:23593480 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
MAPK9 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:23593480 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapkapk2 |
MAP kinase-activated protein kinase 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Benzo(a)pyrene results in increased degradation of MAPKAPK2 protein] |
CTD |
PMID:35427736 |
|
NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of MARCHF6 protein |
CTD |
PMID:30545937 |
|
NCBI chr15:31,456,045...31,531,172
Ensembl chr15:31,456,037...31,531,199
|
|
G |
Masp1 |
MBL associated serine protease 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MASP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:23,261,778...23,340,127
Ensembl chr16:23,268,167...23,339,565
|
|
G |
Mb |
myoglobin |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870
|
|
G |
Mbd2 |
methyl-CpG binding domain protein 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MBD2 protein] |
CTD |
PMID:23395981 |
|
NCBI chr18:70,701,298...70,761,769
Ensembl chr18:70,701,260...70,759,202
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MBD3 protein] |
CTD |
PMID:23395981 |
|
NCBI chr10:80,228,373...80,235,365
Ensembl chr10:80,228,373...80,235,384
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
multiple interactions increases ubiquitination decreases degradation increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Resveratrol co-treated with Clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenite results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Clofarabine promotes the reaction [Resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Daunorubicin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Resveratrol promotes the reaction [Clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [USP7 protein affects the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Wortmannin inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Resveratrol co-treated with Clofarabine] results in increased expression of MCL1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of MCL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of MCL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MCL1 protein |
CTD |
PMID:16109713 PMID:17553788 PMID:20802529 PMID:21750559 PMID:21933852 PMID:23082001 PMID:23341456 PMID:23353698 PMID:24924397 PMID:25408576 PMID:28673964 PMID:32305283 PMID:32802178 PMID:34963561 PMID:35561756 PMID:36346691 More...
|
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MCM5 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:75,836,096...75,855,067
Ensembl chr 8:75,836,197...75,855,067
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MDM2 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]] |
CTD |
PMID:17575151 PMID:20061341 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ethanol results in increased degradation of MECP2 protein] |
CTD |
PMID:23395981 |
|
NCBI chr X:73,070,198...73,129,296
Ensembl chr X:73,070,198...73,129,296
|
|
G |
Mgarp |
mitochondria localized glutamic acid rich protein |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MGARP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:51,295,833...51,303,968
Ensembl chr 3:51,295,833...51,304,159
|
|
G |
Mgll |
monoglyceride lipase |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MGLL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:88,701,397...88,805,342
Ensembl chr 6:88,701,394...88,805,342
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tamoxifen results in increased degradation of MGMT protein] |
CTD |
PMID:17597106 |
|
NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MGST1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
Mir122 |
microRNA 122 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MIR122 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr18:65,381,932...65,381,997
Ensembl chr18:65,381,932...65,381,997
|
|
G |
Mir146 |
microRNA 146 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MIR146A |
CTD |
PMID:32392329 |
|
NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288
|
|
G |
Mitf |
melanogenesis associated transcription factor |
multiple interactions decreases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] which results in decreased ubiquitination of MITF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phytol inhibits the reaction [alpha-MSH results in increased expression of MITF protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MITF mRNA |
CTD |
PMID:29486182 PMID:31806706 |
|
NCBI chr 6:97,783,966...97,998,321
Ensembl chr 6:97,784,013...97,998,310
|
|
G |
Mlkl |
mixed lineage kinase domain-like |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:112,037,879...112,065,081
Ensembl chr 8:112,038,429...112,064,809
|
|
G |
Mllt11 |
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLLT11 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:95,125,852...95,139,486
Ensembl chr 3:95,126,446...95,139,482
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [halofuginone results in increased expression of MMP13 mRNA] |
CTD |
PMID:16489207 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MMP23 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 4:155,735,111...155,738,982
Ensembl chr 4:155,735,112...155,737,841
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [butein results in decreased expression of MMP9 protein] |
CTD |
PMID:15728660 PMID:20696233 PMID:24613819 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCOS mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr18:24,786,538...24,834,634
Ensembl chr18:24,786,748...24,834,632
|
|
G |
Mocs1 |
molybdenum cofactor synthesis 1 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr17:49,735,378...49,762,463
Ensembl chr17:49,735,390...49,762,463
|
|
G |
Mocs2 |
molybdenum cofactor synthesis 2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:114,954,707...114,965,960
Ensembl chr13:114,954,772...114,968,811
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MT3 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774
|
|
G |
Mterf3 |
mitochondrial transcription termination factor 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein] |
CTD |
PMID:35904214 |
|
NCBI chr13:67,053,520...67,081,148
Ensembl chr13:67,055,032...67,081,152
|
|
G |
Mthfd1 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenic trioxide results in increased degradation of MTHFD1 protein] |
CTD |
PMID:28265077 |
|
NCBI chr12:76,301,180...76,366,594
Ensembl chr12:76,302,072...76,366,577
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MTTP protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Chloroquine] results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Mtus1 |
mitochondrial tumor suppressor 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MTUS1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:41,443,949...41,587,318
Ensembl chr 8:41,443,951...41,586,763
|
|
G |
Muc1 |
mucin 1, transmembrane |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [MUC1 affects the expression of EGFR protein] |
CTD |
PMID:22457794 |
|
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
|
|
G |
Muc5ac |
mucin 5, subtypes A and C, tracheobronchial/gastric |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 |
|
NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968
|
|
G |
Mybpc3 |
myosin binding protein C, cardiac |
decreases expression multiple interactions affects response to substance |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPC3 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of BOK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CAV1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CCNB1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDH3 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CDK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of CKB mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of EGFL7 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of FAHD1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of G0S2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of GPR146 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC10 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC12 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC13 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC15 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC22 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of H2AC7 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HAGHL mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of HOPX mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KBTBD11 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of KY mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LGALS1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC10 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of LRRC75A mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MCM5 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MMP23 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYL12B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of NRM mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PBK mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PDLIM4 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLEKHG2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPARGC1B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPP1R3G mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ROBO4 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of RRM2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of SYNPO mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TK1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176A mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TRIB2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ZFYVE21 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of ATG12 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of EIF2AK2 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of FAM13B mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of GADD45G mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of HSPA8 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of LUC7L mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of NRIP3 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SF1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SWT1 mRNA; [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of UFD1 mRNA; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACAA2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ACTC1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ADSS1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of APH1A mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ARG1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ART3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of C1QB mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAR14 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CAVIN1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CENPA mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CHRM2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CKMT2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CLIP4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CMYA5 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of CORIN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of EGLN3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ENO3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of FBXO10 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GSG1L mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GUCY1A1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of GYG1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of H2-AB1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HES1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HIGD1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HR mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of HSPB2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of KLHL6 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LDB3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LMO7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LRRC10 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of LXN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MB mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPC3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PIP5K1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLAC8 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SH3KBP1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SNRK mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPON2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPSB4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SSPN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TFRC mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of THY1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMEM204 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMOD1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI2 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TSC22D4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UNC13C mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ZBTB8B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CD14 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of CLDN4 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DNMT3L mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of DYNC1H1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GDF15 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of INSL6 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of KIF1A mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MAP1B mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MLKL mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MOCS1 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MT3 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NGF mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDPN mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC6A9 mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SPRR2G mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SYBU mRNA]; MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TENM4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:90,948,459...90,966,862
Ensembl chr 2:90,948,489...90,966,861
|
|
G |
Mybphl |
myosin binding protein H-like |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYBPHL mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:108,272,227...108,287,373
Ensembl chr 3:108,272,227...108,287,373
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one inhibits the reaction [STK11 mutant form results in increased expression of MYC protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [deguelin results in decreased expression of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Drugs, Chinese Herbal results in decreased expression of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel sulfate results in increased degradation of MYC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in decreased expression of MYC protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein [arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of MYC protein; [arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of MYC protein modified form; arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:20046830 PMID:20945414 PMID:21472727 PMID:23593480 PMID:24457827 PMID:24793789 PMID:25897075 PMID:28548306 More...
|
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Myh6 |
myosin, heavy polypeptide 6, cardiac muscle, alpha |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYH6 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384
|
|
G |
Myl1 |
myosin, light polypeptide 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 1:66,963,454...66,987,091
Ensembl chr 1:66,963,454...66,984,563
|
|
G |
Myl12b |
myosin, light chain 12B, regulatory |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYL12B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:71,280,958...71,297,511
Ensembl chr17:71,280,128...71,297,885
|
|
G |
Myl7 |
myosin, light polypeptide 7, regulatory |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYL7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:5,846,637...5,848,782
Ensembl chr11:5,846,637...5,848,782
|
|
G |
Mylk |
myosin, light polypeptide kinase |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYLK3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:86,050,933...86,112,969
Ensembl chr 8:86,050,932...86,112,974
|
|
G |
Myo5b |
myosin VB |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYO5B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr18:74,575,435...74,905,769
Ensembl chr18:74,574,007...74,904,564
|
|
G |
Myzap |
myocardial zonula adherens protein |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of MYZAP mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:71,411,629...71,499,642
Ensembl chr 9:71,411,629...71,499,642
|
|
G |
Nacad |
NAC alpha domain containing |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NACAD mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr11:6,547,814...6,556,059
Ensembl chr11:6,547,823...6,556,053
|
|
G |
Nanog |
Nanog homeobox |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of NANOG protein] |
CTD |
PMID:23651583 |
|
NCBI chr 6:122,684,448...122,691,592
Ensembl chr 6:122,684,448...122,691,592
|
|
G |
Napb |
N-ethylmaleimide sensitive fusion protein attachment protein beta |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NAPB mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:148,535,905...148,574,396
Ensembl chr 2:148,535,905...148,574,387
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in increased degradation of NCOA3 protein] |
CTD |
PMID:16456540 |
|
NCBI chr 2:165,834,557...165,915,162
Ensembl chr 2:165,834,545...165,915,162
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of NCOR1 protein |
CTD |
PMID:15857753 |
|
NCBI chr11:62,207,132...62,348,200
Ensembl chr11:62,207,252...62,349,367
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of NCOR2 protein |
CTD |
PMID:15857753 |
|
NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283
|
|
G |
Ndfip1 |
Nedd4 family interacting protein 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NDFIP1 protein results in decreased expression of SLC6A3 protein] |
CTD |
PMID:26300475 |
|
NCBI chr18:38,551,960...38,598,250
Ensembl chr18:38,543,449...38,598,356
|
|
G |
Nedd4l |
neural precursor cell expressed, developmentally down-regulated gene 4-like |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NEDD4L mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:65,017,551...65,350,888
Ensembl chr18:65,020,776...65,350,899
|
|
G |
Neurl2 |
neuralized E3 ubiquitin protein ligase 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NEURL2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:164,672,650...164,675,516
Ensembl chr 2:164,672,652...164,675,376
|
|
G |
Nfat5 |
nuclear factor of activated T cells 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in increased degradation of NFAT5 protein] |
CTD |
PMID:17105721 |
|
NCBI chr 8:108,020,072...108,106,149
Ensembl chr 8:108,020,102...108,106,149
|
|
G |
Nfe2l1 |
nuclear factor, erythroid derived 2,-like 1 |
decreases degradation multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NFE2L1 protein alternative form benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein]; Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein]; Metformin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein] |
CTD |
PMID:28549828 PMID:33838154 |
|
NCBI chr11:96,708,239...96,720,810
Ensembl chr11:96,708,240...96,720,794
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions increases expression decreases degradation increases activity increases ubiquitination decreases expression |
ISO EXP |
2-tert-butyl-4-quinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; 2-tert-butylhydroquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of and affects the localization of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of NFE2L2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dichlorodiphenyl Dichloroethylene results in decreased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Homocysteine results in decreased phosphorylation of and results in decreased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased stability of and results in increased ubiquitination of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased localization of and results in increased activity of NFE2L2 protein; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; cyanoginosin LR inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; hydroquinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; Metformin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GCLC mRNA]; NFE2L2 protein promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HMOX1 mRNA]; quinone inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein] [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein [2-tert-butylhydroquinone co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of and results in increased ubiquitination of NFE2L2 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 2-tert-butylhydroquinone] results in increased expression of NFE2L2 protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [2-tert-butylhydroquinone results in increased ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cadmium Chloride affects the ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to KEAP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and affects the localization of NFE2L2 protein; Exenatide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NFE2L2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of NFE2L2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [triptolide affects the expression of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [N-acetylsphingosine results in decreased localization of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NFE2L2 protein inhibits the reaction [Streptozocin results in increased expression of USP15 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptolide results in increased ubiquitination of NFE2L2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sulforaphane results in increased activity of NFE2L2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NFE2L2 protein modified form |
CTD |
PMID:12441344 PMID:12446695 PMID:14510636 PMID:15319326 PMID:15322212 PMID:18512965 PMID:18550526 PMID:19786557 PMID:20722399 PMID:20806931 PMID:22019695 PMID:22558124 PMID:22606287 PMID:22964297 PMID:25263748 PMID:26598004 PMID:27939242 PMID:28645578 PMID:29618784 PMID:30186748 PMID:30703377 PMID:30926361 PMID:31319135 PMID:31806706 PMID:33434570 PMID:33838154 PMID:34758851 PMID:35478295 PMID:38016618 More...
|
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of [NFKB1 protein binds to RELA protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of [NFKB1 protein binds to RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]] |
CTD |
PMID:11543732 PMID:14527959 PMID:14581482 PMID:16026644 PMID:24457827 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions increases phosphorylation increases expression increases expression |
ISO EXP |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with TNF protein] results in increased phosphorylation of NFKBIA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [osthol results in decreased phosphorylation of and results in decreased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Deoxycholic Acid results in increased phosphorylation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of and results in increased degradation of NFKBIA protein; MAP1LC3B protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of NFKBIA protein]; sodium arsenite inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with IL1B protein] results in increased expression of and results in increased phosphorylation of NFKBIA protein]; TNF protein affects the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Thiopental] affects the phosphorylation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased phosphorylation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ammonium Chloride results in increased degradation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFKBIA protein MG132 pretreatment increases expression of protein in liver of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11543732 PMID:11698246 PMID:11835394 PMID:11923223 PMID:12185005 PMID:12628480 PMID:12721113 PMID:12883408 PMID:15477007 PMID:16421291 PMID:17644113 PMID:20005289 PMID:22503731 PMID:23423712 PMID:24085292 PMID:25780039 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIB protein] |
CTD |
PMID:11543732 |
|
NCBI chr 7:28,457,676...28,466,069
Ensembl chr 7:28,457,676...28,466,937
|
|
G |
Nfkbie |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, epsilon |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIE protein] |
CTD |
PMID:12185005 |
|
NCBI chr17:45,866,626...45,874,095
Ensembl chr17:45,866,629...45,874,095
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NGF mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Ngly1 |
N-glycanase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NGLY1 protein binds to UBXN1 protein] |
CTD |
PMID:15362974 |
|
NCBI chr14:6,157,837...6,220,449
Ensembl chr14:6,157,837...6,220,483
|
|
G |
Nipsnap2 |
nipsnap homolog 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NIPSNAP2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:129,802,080...129,835,391
Ensembl chr 5:129,802,127...129,835,391
|
|
G |
Nme3 |
NME/NM23 nucleoside diphosphate kinase 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NME3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:25,115,474...25,116,505
Ensembl chr17:25,115,474...25,116,496
|
|
G |
Nmrk2 |
nicotinamide riboside kinase 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NMRK2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:81,034,004...81,037,871
Ensembl chr10:81,034,004...81,037,885
|
|
G |
Nol3 |
nucleolar protein 3 (apoptosis repressor with CARD domain) |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [Doxorubicin results in increased degradation of NOL3 protein] |
CTD |
PMID:19139834 |
|
NCBI chr 8:106,002,777...106,008,571
Ensembl chr 8:106,002,772...106,008,571
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions decreases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [pirinixic acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased expression of NOS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NOS2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ammonium Chloride results in increased expression of NOS2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]] |
CTD |
PMID:11923223 PMID:12628480 PMID:12721113 PMID:17891158 PMID:19376148 PMID:19393675 PMID:20675566 PMID:23395999 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
decreases degradation increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of NOS3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOS3 protein |
CTD |
PMID:20229525 PMID:20675566 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Notch1 |
notch 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NOTCH1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of NOTCH1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [triptonide results in increased degradation of NOTCH1 protein] |
CTD |
PMID:24497960 PMID:24801890 PMID:31597699 PMID:31866380 |
|
NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 mRNA; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in increased expression of NQO1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NFE2L2 protein binds to NQO1 promoter] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NQO1 protein |
CTD |
PMID:16243960 PMID:20061341 PMID:22606287 PMID:30186748 PMID:33434570 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases expression decreases activity increases ubiquitination |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [DNAJC7 protein results in increased expression of NR1I3 protein]; NR1I3 protein affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of DNAJC7 protein]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NR1I3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime affects the localization of NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate results in increased activity of NR1I3 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [GRIP1 protein binds to NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Phenobarbital affects the localization of NR1I3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SRC protein binds to NR1I3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of NR1I3 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NR1I3 protein |
CTD |
PMID:24224465 PMID:24789201 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NR3C1 mRNA |
CTD |
PMID:20619282 PMID:31778773 PMID:31806706 |
|
NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KU-32 compound inhibits the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NRG1 protein results in increased expression of and results in increased phosphorylation of JUN protein] |
CTD |
PMID:23240583 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of NRIP3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:109,357,263...109,380,752
Ensembl chr 7:109,357,262...109,381,232
|
|
G |
Nrm |
nurim (nuclear envelope membrane protein) |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of NRM mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:36,171,987...36,176,292
Ensembl chr17:36,172,210...36,176,294
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [3-deazaneplanocin results in increased degradation of NSD2 protein] |
CTD |
PMID:32001260 |
|
NCBI chr 5:33,974,286...34,055,310
Ensembl chr 5:33,978,069...34,055,319
|
|
G |
Nuf2 |
NUF2, NDC80 kinetochore complex component |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of NUF2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 1:169,325,503...169,359,033
Ensembl chr 1:169,325,503...169,359,033
|
|
G |
Nupr1 |
nuclear protein transcription regulator 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NUPR1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
|
|
G |
Ogg1 |
8-oxoguanine DNA-glycosylase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TH5487 inhibits the reaction [TGFB1 protein results in increased expression of OGG1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [TGFB1 protein results in increased expression of OGG1 protein] |
CTD |
PMID:35654123 |
|
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of OPA1 protein alternative form |
CTD |
PMID:20678484 |
|
NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]] |
CTD |
PMID:21600884 |
|
NCBI chr 4:131,834,980...131,872,042
Ensembl chr 4:131,838,037...131,871,797
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of OSGIN1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr 8:120,160,874...120,172,996
Ensembl chr 8:120,160,863...120,172,995
|
|
G |
P2rx6 |
purinergic receptor P2X, ligand-gated ion channel, 6 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of P2RX6 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr16:17,379,749...17,389,879
Ensembl chr16:17,379,749...17,395,664
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
multiple interactions decreases response to substance |
ISO |
PARK7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HSPA1A protein] PARK7 protein results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Paraquat results in increased sulfation of and results in increased oxidation of PARK7 protein] |
CTD |
PMID:18331584 PMID:26409479 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:16051428 PMID:18790767 PMID:20100472 PMID:34418242 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pax2 |
paired box 2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PAX2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:44,735,040...44,826,708
Ensembl chr19:44,735,057...44,826,310
|
|
G |
Pbk |
PDZ binding kinase |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PBK mRNA |
CTD |
PMID:25566086 |
|
NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271
|
|
G |
Pcdh7 |
protocadherin 7 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PCDH7 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:57,873,487...58,290,578
Ensembl chr 5:57,875,309...58,290,572
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDCD6IP protein |
CTD |
PMID:21692457 |
|
NCBI chr 9:113,480,812...113,537,457
Ensembl chr 9:113,480,812...113,537,327
|
|
G |
Pdgfb |
platelet derived growth factor, B polypeptide |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDGFB mRNA |
CTD |
PMID:15728660 PMID:25566086 |
|
NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDK1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
|
|
G |
Pdlim4 |
PDZ and LIM domain 4 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PDLIM4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:53,945,754...53,959,814
Ensembl chr11:53,945,754...53,959,840
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDLIM5 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:141,945,346...142,101,480
Ensembl chr 3:141,945,351...142,101,454
|
|
G |
Pdpn |
podoplanin |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PDPN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:142,993,979...143,026,134
Ensembl chr 4:142,994,001...143,026,134
|
|
G |
Pdxp |
pyridoxal (pyridoxine, vitamin B6) phosphatase |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PDXP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:78,796,342...78,803,717
Ensembl chr15:78,798,119...78,803,717
|
|
G |
Pdyn |
prodynorphin |
decreases secretion |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased secretion of PDYN protein alternative form |
CTD |
PMID:17670969 |
|
NCBI chr 2:129,528,469...129,541,858
Ensembl chr 2:129,528,485...129,541,764
|
|
G |
Perm1 |
PPARGC1 and ESRR induced regulator, muscle 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PERM1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:156,287,724...156,305,766
Ensembl chr 4:156,300,325...156,305,764
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PFKFB3 protein |
CTD |
PMID:19448625 |
|
NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888
|
|
G |
Pfkp |
phosphofructokinase, platelet |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PFKP mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr13:6,629,910...6,699,096
Ensembl chr13:6,629,804...6,698,813
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PGR protein |
CTD |
PMID:15218360 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pin1 |
peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arsenic Trioxide results in decreased expression of PIN1 protein] |
CTD |
PMID:30093655 |
|
NCBI chr 9:20,563,335...20,575,008
Ensembl chr 9:20,563,391...20,577,880
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[ponasterone A results in increased expression of PINK1 protein] which results in decreased expression of FIS1 protein] |
CTD |
PMID:20164189 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase, type 1 beta |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PIP5K1B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr19:24,272,158...24,533,236
Ensembl chr19:24,272,158...24,533,236
|
|
G |
Pkd1 |
polycystin 1, transient receptor potential channel interacting |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [STA 9090 inhibits the reaction [PKD1 gene mutant form results in increased expression of BRD4 protein]] |
CTD |
PMID:25877301 |
|
NCBI chr17:24,767,657...24,815,457
Ensembl chr17:24,768,808...24,815,482
|
|
G |
Pkig |
protein kinase inhibitor, gamma |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PKIG mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:163,500,306...163,568,078
Ensembl chr 2:163,500,306...163,568,078
|
|
G |
Plac8 |
placenta-specific 8 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLAC8 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:100,699,455...100,720,119
Ensembl chr 5:100,701,591...100,720,111
|
|
G |
Plekha6 |
pleckstrin homology domain containing, family A member 6 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLEKHA6 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:133,089,770...133,231,173
Ensembl chr 1:133,091,948...133,231,173
|
|
G |
Plekhg2 |
pleckstrin homology domain containing, family G (with RhoGef domain) member 2 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLEKHG2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:28,059,028...28,072,818
Ensembl chr 7:28,059,029...28,072,024
|
|
G |
Plk1 |
polo like kinase 1 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PLK1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:121,758,658...121,769,107
Ensembl chr 7:121,758,662...121,769,096
|
|
G |
Pln |
phospholamban |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLN mRNA |
CTD |
PMID:25566086 |
|
NCBI chr10:53,213,782...53,222,095
Ensembl chr10:53,213,763...53,222,083
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLOD3 protein |
CTD |
PMID:21692457 |
|
NCBI chr 5:137,015,873...137,025,500
Ensembl chr 5:137,015,873...137,025,502
|
|
G |
Plvap |
plasmalemma vesicle associated protein |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PLVAP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:71,950,397...71,964,446
Ensembl chr 8:71,950,409...71,964,396
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
decreases degradation increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PMAIP1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA MAPK8 affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA]; MAPK9 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:20802529 PMID:23593480 PMID:31806706 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Pml |
promyelocytic leukemia |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PML protein modified form |
CTD |
PMID:26049103 |
|
NCBI chr 9:58,125,359...58,157,077
Ensembl chr 9:58,125,359...58,157,069
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:84,052,017...84,073,720
Ensembl chr15:84,052,038...84,071,437
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of POU5F1 protein |
CTD |
PMID:24497960 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases activity multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of PPARG protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [alitretinoin results in increased activity of PPARG protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of PPARG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [rosiglitazone results in decreased expression of PPARG protein] |
CTD |
PMID:15707588 PMID:18555852 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PPARGC1A protein |
CTD |
PMID:20860658 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Ppargc1b |
peroxisome proliferative activated receptor, gamma, coactivator 1 beta |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPARGC1B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPIA mRNA |
CTD |
PMID:15857753 |
|
NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817
|
|
G |
Ppl |
periplakin |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PPL mRNA |
CTD |
PMID:20061341 |
|
NCBI chr16:4,904,155...4,950,345
Ensembl chr16:4,904,155...4,950,285
|
|
G |
Ppp1r14c |
protein phosphatase 1, regulatory inhibitor subunit 14C |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PPP1R14C mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr10:3,315,974...3,414,975
Ensembl chr10:3,316,057...3,414,975
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PPP1R15A mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein] |
CTD |
PMID:19135031 PMID:25566086 PMID:29109149 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:36,142,816...36,154,371
Ensembl chr13:36,142,822...36,154,371
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRC1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:79,944,224...79,966,007
Ensembl chr 7:79,944,198...79,966,007
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PRDX1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased expression of PRKCB protein] |
CTD |
PMID:17644113 |
|
NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [PRKCD protein results in increased ubiquitination of HNRNPK protein]; Glutathione inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:15707588 PMID:19662097 PMID:19747914 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prkcsh |
protein kinase C substrate 80K-H |
increases response to substance |
EXP |
PRKCSH gene mutant form results in increased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde |
CTD |
PMID:21685914 |
|
NCBI chr 9:21,914,314...21,925,521
Ensembl chr 9:21,914,102...21,925,518
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions decreases expression affects expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [PRKN protein results in decreased expression of SLC11A2 protein alternative form]; Tretinoin affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the expression of PRKN protein alternative form] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRKN mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRKN protein |
CTD |
PMID:18586549 PMID:20089134 PMID:28673964 PMID:28688199 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
|
|
G |
Psma1 |
proteasome subunit alpha 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 7:113,863,785...113,875,351
Ensembl chr 7:113,863,841...113,875,353
|
|
G |
Psma2 |
proteasome subunit alpha 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr13:14,787,827...14,800,258
Ensembl chr13:14,787,825...14,848,821
|
|
G |
Psma3 |
proteasome subunit alpha 3 |
increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA3 mRNA |
CTD |
PMID:15525353 PMID:31806706 |
|
NCBI chr12:71,016,082...71,042,651
Ensembl chr12:71,021,395...71,043,121
|
|
G |
Psma4 |
proteasome subunit alpha 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 9:54,858,074...54,865,316
Ensembl chr 9:54,858,074...54,865,314
|
|
G |
Psma5 |
proteasome subunit alpha 5 |
increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA5 mRNA |
CTD |
PMID:15525353 PMID:31806706 |
|
NCBI chr 3:108,164,242...108,187,268
Ensembl chr 3:108,164,242...108,187,290
|
|
G |
Psma6 |
proteasome subunit alpha 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr12:55,431,007...55,465,244
Ensembl chr12:55,431,007...55,465,239
|
|
G |
Psma7 |
proteasome subunit alpha 7 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMA7 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:179,678,160...179,684,257
Ensembl chr 2:179,678,167...179,684,226
|
|
G |
Psmb10 |
proteasome (prosome, macropain) subunit, beta type 10 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB10 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 8:106,662,360...106,665,024
Ensembl chr 8:106,662,367...106,665,076
|
|
G |
Psmb2 |
proteasome (prosome, macropain) subunit, beta type 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 4:126,571,460...126,603,503
Ensembl chr 4:126,571,423...126,603,507
|
|
G |
Psmb3 |
proteasome (prosome, macropain) subunit, beta type 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:97,594,260...97,604,326
Ensembl chr11:97,594,225...97,604,326
|
|
G |
Psmb4 |
proteasome (prosome, macropain) subunit, beta type 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 3:94,791,635...94,794,269
Ensembl chr 3:94,791,404...94,794,272
|
|
G |
Psmb5 |
proteasome (prosome, macropain) subunit, beta type 5 |
increases expression multiple interactions decreases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB5 mRNA [sodium arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of PSMB5 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased expression of PSMB5 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in decreased expression of PSMB5 protein]; sodium arsenite promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB5 protein |
CTD |
PMID:15525353 PMID:31806706 PMID:32301004 |
|
NCBI chr14:54,851,577...54,855,452
Ensembl chr14:54,851,576...54,855,479
|
|
G |
Psmb6 |
proteasome (prosome, macropain) subunit, beta type 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:70,416,116...70,418,684
Ensembl chr11:70,416,193...70,418,684
|
|
G |
Psmb7 |
proteasome (prosome, macropain) subunit, beta type 7 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB7 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:38,478,058...38,533,964
Ensembl chr 2:38,478,048...38,534,099
|
|
G |
Psmb9 |
proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2) |
decreases expression increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSMB9 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMB9 mRNA |
CTD |
PMID:20061341 PMID:31806706 |
|
NCBI chr17:34,401,006...34,406,347
Ensembl chr17:34,400,961...34,406,738
|
|
G |
Psmc1 |
protease (prosome, macropain) 26S subunit, ATPase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr12:100,076,461...100,089,623
Ensembl chr12:100,076,413...100,089,664
|
|
G |
Psmc2 |
proteasome (prosome, macropain) 26S subunit, ATPase 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 5:21,990,273...22,008,785
Ensembl chr 5:21,990,281...22,008,785
|
|
G |
Psmc3 |
proteasome (prosome, macropain) 26S subunit, ATPase 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:90,884,361...90,889,783
Ensembl chr 2:90,884,354...90,896,714
|
|
G |
Psmc4 |
proteasome (prosome, macropain) 26S subunit, ATPase, 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 7:27,741,127...27,749,517
Ensembl chr 7:27,741,132...27,749,526
|
|
G |
Psmc5 |
protease (prosome, macropain) 26S subunit, ATPase 5 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction and affects the localization of [PSMC5 protein binds to GABBR2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC5 mRNA |
CTD |
PMID:24482233 PMID:31806706 |
|
NCBI chr11:106,147,011...106,153,938
Ensembl chr11:106,146,980...106,153,946
|
|
G |
Psmc6 |
proteasome (prosome, macropain) 26S subunit, ATPase, 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMC6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr14:45,567,285...45,587,150
Ensembl chr14:45,567,245...45,587,162
|
|
G |
Psmd1 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 1:85,992,341...86,067,017
Ensembl chr 1:85,992,109...86,066,873
|
|
G |
Psmd11 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD11 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:80,319,441...80,364,074
Ensembl chr11:80,319,441...80,364,074
|
|
G |
Psmd12 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD12 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:107,370,354...107,388,862
Ensembl chr11:107,370,310...107,395,188
|
|
G |
Psmd13 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD13 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 7:140,462,307...140,478,555
Ensembl chr 7:140,461,881...140,478,556
|
|
G |
Psmd14 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD14 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:61,542,038...61,630,720
Ensembl chr 2:61,542,038...61,630,720
|
|
G |
Psmd2 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr16:20,469,872...20,482,164
Ensembl chr16:20,470,402...20,482,164
|
|
G |
Psmd3 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:98,573,380...98,586,804
Ensembl chr11:98,573,380...98,586,805
|
|
G |
Psmd4 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr 3:94,939,999...94,949,880
Ensembl chr 3:94,940,005...94,949,925
|
|
G |
Psmd6 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr14:8,348,818...8,357,578
Ensembl chr14:8,348,779...8,357,589
|
|
G |
Psmd8 |
proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSMD8 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 7:28,873,612...28,880,098
Ensembl chr 7:28,873,613...28,880,126
|
|
G |
Psme1 |
proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSME1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr14:55,815,951...55,818,984
Ensembl chr14:55,815,580...55,818,986
|
|
G |
Psme2 |
proteasome (prosome, macropain) activator subunit 2 (PA28 beta) |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PSME2 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr14:55,824,897...55,828,558
Ensembl chr14:55,824,898...55,828,570
|
|
G |
Psme4 |
proteasome (prosome, macropain) activator subunit 4 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PSME4 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr11:30,721,753...30,831,150
Ensembl chr11:30,721,726...30,830,361
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression increases ubiquitination |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zinc Sulfate results in decreased stability of PTEN protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTEN protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of PTEN protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of PTEN protein modified form |
CTD |
PMID:17684018 PMID:20100827 PMID:24449419 PMID:33256086 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptger1 |
prostaglandin E receptor 1 (subtype EP1) |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] |
CTD |
PMID:20335389 |
|
NCBI chr 8:84,393,171...84,399,385
Ensembl chr 8:84,393,307...84,399,382
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
decreases degradation multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PTGES3 protein 4-tosylcyclonovobiocic acid promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of PTGES3 protein] |
CTD |
PMID:19118525 |
|
NCBI chr10:127,894,851...127,913,123
Ensembl chr10:127,894,823...127,913,141
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased expression of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTGS2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PTGS2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of PTGS2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein] |
CTD |
PMID:11230753 PMID:12628480 PMID:12721113 PMID:17084486 PMID:18457675 PMID:22767315 PMID:24085292 More...
|
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2b |
PTK2 protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [PTK2B protein affects the ubiquitination of ESR1 protein] |
CTD |
PMID:29428397 |
|
NCBI chr14:66,390,706...66,518,549
Ensembl chr14:66,390,706...66,518,501
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4a3 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PTP4A3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:73,594,991...73,629,075
Ensembl chr15:73,594,994...73,630,615
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
PTPN1 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:28359145 |
|
NCBI chr 2:167,772,670...167,821,305
Ensembl chr 2:167,773,977...167,821,305
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RAB33A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr X:47,602,540...47,619,112
Ensembl chr X:47,608,162...47,619,109
|
|
G |
Rabl6 |
RAB, member RAS oncogene family-like 6 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RABL6 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:25,473,029...25,498,493
Ensembl chr 2:25,473,030...25,498,533
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Mitomycin co-treated with Curcumin] results in decreased expression of RAD51 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Mitomycin results in increased expression of RAD51 protein]] |
CTD |
PMID:21810436 |
|
NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] |
CTD |
PMID:27794399 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Ramp1 |
receptor (calcitonin) activity modifying protein 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RAMP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:91,107,544...91,152,918
Ensembl chr 1:91,107,544...91,152,918
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases ubiquitination multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RARA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in decreased expression of RARA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in increased degradation of RARA protein] |
CTD |
PMID:20945414 PMID:24819975 |
|
NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768
|
|
G |
Rarres2 |
retinoic acid receptor responder (tazarotene induced) 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RARRES2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:48,546,630...48,549,778
Ensembl chr 6:48,546,630...48,549,723
|
|
G |
Rassf5 |
Ras association (RalGDS/AF-6) domain family member 5 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RASSF5 protein results in decreased expression of CTNNB1 protein] |
CTD |
PMID:25217643 |
|
NCBI chr 1:131,104,147...131,172,915
Ensembl chr 1:131,104,147...131,172,995
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
increases expression multiple interactions increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBL1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein] |
CTD |
PMID:20100483 |
|
NCBI chr 2:156,987,813...157,046,454
Ensembl chr 2:156,987,813...157,046,454
|
|
G |
Rbp3 |
retinol binding protein 3, interstitial |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of RBP3 protein mutant form |
CTD |
PMID:23486466 |
|
NCBI chr14:33,675,960...33,686,176
Ensembl chr14:33,675,960...33,686,173
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 5:53,713,121...53,814,787
Ensembl chr 5:53,623,494...53,814,704
|
|
G |
Rcn2 |
reticulocalbin 2 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RCN2 protein |
CTD |
PMID:21692457 |
|
NCBI chr 9:55,949,129...55,966,367
Ensembl chr 9:55,949,129...55,969,166
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
increases activity decreases activity multiple interactions affects localization increases ubiquitination decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of RELA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [halofuginone affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan affects the localization of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of RELA protein Acetylcysteine inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [(+)-JQ1 compound affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cisplatin promotes the reaction [RELA protein binds to TP63 protein alternative form]] which results in increased degradation of TP63 protein alternative form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BRD4 mutant form affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [CIGB-552 peptide results in decreased expression of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Deoxycholic Acid results in increased localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of [NFKB1 protein binds to RELA protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trimethyltin chloride affects the localization of RELA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased activity of [NFKB1 protein binds to RELA protein]; SB 203580 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RELA protein MG132 pretreatment decreases expression of protein in liver of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11543732 PMID:12628480 PMID:12721113 PMID:14527959 PMID:14581482 PMID:15498850 PMID:16026644 PMID:16489207 PMID:17644113 PMID:18457675 PMID:21088498 PMID:22766066 PMID:23401744 PMID:23423712 PMID:23686307 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rgma |
repulsive guidance molecule family member A |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RGMA mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:73,025,268...73,069,647
Ensembl chr 7:73,025,257...73,069,647
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SMURF1 protein results in increased degradation of RHOB protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of RHOB protein] |
CTD |
PMID:30587574 PMID:31140275 |
|
NCBI chr12:8,547,661...8,550,009
Ensembl chr12:8,547,661...8,550,009
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF168 protein results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr 3:104,696,350...104,701,775
Ensembl chr 3:104,695,691...104,701,775
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of and results in increased ubiquitination of RICTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882
|
|
G |
Rnf144b |
ring finger protein 144B |
decreases degradation multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of RNF144B protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile inhibits the reaction [Estrogens deficiency results in decreased degradation of RNF144B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile results in increased degradation of RNF144B protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride inhibits the reaction [Estrogens deficiency results in decreased degradation of RNF144B protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lithium Chloride results in increased degradation of RNF144B protein] |
CTD |
PMID:29724995 |
|
NCBI chr13:47,276,196...47,401,470
Ensembl chr13:47,276,132...47,401,467
|
|
G |
Rnf168 |
ring finger protein 168 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF168 protein results in decreased expression of RHOC protein] |
CTD |
PMID:34873829 |
|
NCBI chr16:32,096,279...32,120,260
Ensembl chr16:32,096,277...32,120,252
|
|
G |
Rnf187 |
ring finger protein 187 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Ro 31-8220 results in decreased stability of RNF187 protein] |
CTD |
PMID:25851810 |
|
NCBI chr11:58,823,114...58,829,732
Ensembl chr11:58,823,114...58,829,742
|
|
G |
Rnf208 |
ring finger protein 208 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of RNF208 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:25,132,941...25,134,273
Ensembl chr 2:25,132,941...25,134,274
|
|
G |
Rnf31 |
ring finger protein 31 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF31 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNFAIP3 protein]] |
CTD |
PMID:34416243 |
|
NCBI chr14:55,829,199...55,841,131
Ensembl chr14:55,829,165...55,841,150
|
|
G |
Robo4 |
roundabout guidance receptor 4 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ROBO4 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:37,313,198...37,325,319
Ensembl chr 9:37,313,193...37,326,411
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
multiple interactions decreases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 PMID:31645432 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RPTOR protein |
CTD |
PMID:25897075 |
|
NCBI chr11:119,493,731...119,790,417
Ensembl chr11:119,493,731...119,790,402
|
|
G |
Rrm2 |
ribonucleotide reductase M2 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of RRM2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions increases expression |
ISO |
[alitretinoin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the localization of RXRA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alitretinoin results in increased degradation of RXRA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased degradation of RXRA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of and results in increased expression of RXRA protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RXRA protein |
CTD |
PMID:12970875 PMID:15707588 PMID:17170071 PMID:22310326 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SAE1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 7:16,054,161...16,121,821
Ensembl chr 7:16,054,159...16,121,731
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of SCARB1 protein] |
CTD |
PMID:22442701 |
|
NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:94,840,394...94,852,069
Ensembl chr 3:94,840,367...94,852,069
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression increases ubiquitination |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Lipopolysaccharides inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of SESN2 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SESN2 protein |
CTD |
PMID:25637945 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Set |
SET nuclear oncogene |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SET protein |
CTD |
PMID:21692457 |
|
NCBI chr 2:29,952,074...29,962,589
Ensembl chr 2:29,947,390...29,962,589
|
|
G |
Sf1 |
splicing factor 1 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SF1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr19:6,413,952...6,428,060
Ensembl chr19:6,413,720...6,428,060
|
|
G |
Sh3kbp1 |
SH3-domain kinase binding protein 1 |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SH3KBP1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr X:158,409,888...158,758,916
Ensembl chr X:158,410,268...158,761,065
|
|
G |
Siah1b |
siah E3 ubiquitin protein ligase 1B |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SIAH1B mRNA |
CTD |
PMID:20061341 |
|
NCBI chr X:162,853,699...162,859,489
Ensembl chr X:162,853,701...162,859,489
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SIAH2 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 3:58,582,370...58,599,857
Ensembl chr 3:58,582,359...58,599,821
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ERCC6 gene mutant form results in decreased expression of SIRT1 protein] |
CTD |
PMID:25440059 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sirt6 |
sirtuin 6 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SIRT6 protein results in decreased expression of EP300 protein] |
CTD |
PMID:27094368 |
|
NCBI chr10:81,457,621...81,463,631
Ensembl chr10:81,457,619...81,463,631
|
|
G |
Skp1 |
S-phase kinase-associated protein 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SKP1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr11:52,121,349...52,137,685
Ensembl chr11:52,122,822...52,137,685
|
|
G |
Skp2 |
S-phase kinase-associated protein 2 |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SKP2 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SKP2 protein results in decreased expression of DUSP1 protein] |
CTD |
PMID:20061341 PMID:34697729 |
|
NCBI chr15:9,112,070...9,155,512
Ensembl chr15:9,112,073...9,155,512
|
|
G |
Slbp |
stem-loop binding protein |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of SLBP protein] |
CTD |
PMID:25266719 |
|
NCBI chr 5:33,797,399...33,809,918
Ensembl chr 5:33,792,296...33,809,918
|
|
G |
Slc10a2 |
solute carrier family 10, member 2 |
increases expression multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC10A2 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of SLC10A2 protein] |
CTD |
PMID:23872411 PMID:24498857 |
|
NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351
|
|
G |
Slc11a2 |
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [PRKN protein results in decreased expression of SLC11A2 protein alternative form] |
CTD |
PMID:20089134 |
|
NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953
|
|
G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC29A1 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr17:45,896,126...45,910,544
Ensembl chr17:45,896,126...45,910,532
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC2A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of SLC2A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of SLC2A1 protein] |
CTD |
PMID:17442736 PMID:31850806 PMID:32461003 |
|
NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180
|
|
G |
Slc31a1 |
solute carrier family 31, member 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cisplatin results in increased degradation of SLC31A1 protein] |
CTD |
PMID:17108132 |
|
NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006
|
|
G |
Slc39a4 |
solute carrier family 39 (zinc transporter), member 4 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zinc results in increased degradation of SLC39A4 protein] |
CTD |
PMID:17202136 |
|
NCBI chr15:76,496,583...76,501,579
Ensembl chr15:76,496,583...76,501,584
|
|
G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NDFIP1 protein results in decreased expression of SLC6A3 protein] |
CTD |
PMID:26300475 |
|
NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791
|
|
G |
Slc6a9 |
solute carrier family 6 (neurotransmitter transporter, glycine), member 9 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC6A9 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC6A9 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:117,692,240...117,726,502
Ensembl chr 4:117,691,703...117,732,395
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC7A11 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Slc7a3 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SLC7A3 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr X:100,122,752...100,134,058
Ensembl chr X:100,122,816...100,129,626
|
|
G |
Sln |
sarcolipin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SLN mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 9:53,757,535...53,761,133
Ensembl chr 9:53,757,448...53,761,844
|
|
G |
Smtnl2 |
smoothelin-like 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SMTNL2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr11:72,279,989...72,302,539
Ensembl chr11:72,279,990...72,302,539
|
|
G |
Smurf1 |
SMAD specific E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SMURF1 protein results in increased degradation of RHOB protein] |
CTD |
PMID:30587574 |
|
NCBI chr 5:144,813,305...144,902,657
Ensembl chr 5:144,813,305...144,902,657
|
|
G |
Snca |
synuclein, alpha |
increases phosphorylation multiple interactions |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of SNCA protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of and results in increased ubiquitination of NFE2L2 protein; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein] |
CTD |
PMID:33157086 PMID:38016618 |
|
NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
|
|
G |
Snrk |
SNF related kinase |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SNRK mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SNRK mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:121,946,332...121,998,768
Ensembl chr 9:121,946,332...121,998,768
|
|
G |
Soat2 |
sterol O-acyltransferase 2 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SOAT2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr15:102,058,853...102,071,871
Ensembl chr15:102,058,961...102,071,904
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
decreases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SOCS3 protein |
CTD |
PMID:23782265 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions increases expression decreases expression |
ISO EXP |
[sodium arsenite co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of SOD1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[SOD1 protein results in increased susceptibility to Thimerosal] which results in decreased expression of KCNIP3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC2 protein results in increased degradation of SOD1 protein mutant form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [BIRC3 protein results in increased degradation of SOD1 protein mutant form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Glucose deficiency results in increased degradation of SOD1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of SOD1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [sodium arsenite results in increased expression of SOD1 mRNA]; sodium arsenite inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SOD1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SOD1 mRNA |
CTD |
PMID:17309078 PMID:20061341 PMID:27773815 PMID:30503815 PMID:32301004 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of SOD2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; CAT protein inhibits the reaction [[SOD2 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of HDAC2 protein] |
CTD |
PMID:12161520 PMID:24973648 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sort1 |
sortilin 1 |
multiple interactions decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tetrabromocinnamic acid results in increased degradation of SORT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [wortmannin results in increased degradation of SORT1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SORT1 protein |
CTD |
PMID:25805502 |
|
NCBI chr 3:108,191,272...108,268,835
Ensembl chr 3:108,191,398...108,268,827
|
|
G |
Sox18 |
SRY (sex determining region Y)-box 18 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SOX18 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:181,311,630...181,313,433
Ensembl chr 2:181,311,629...181,313,433
|
|
G |
Sox9 |
SRY (sex determining region Y)-box 9 |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SRY protein mutant form] which results in increased expression of SOX9 mRNA |
CTD |
PMID:27576690 |
|
NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
multiple interactions |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [SP1 protein binds to ARNT promoter]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of and results in increased activity of SP1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of SP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Daunorubicin results in decreased expression of SP1 protein] |
CTD |
PMID:14529614 PMID:17409431 PMID:34963561 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Sp3 |
trans-acting transcription factor 3 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SP3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SP3 protein |
CTD |
PMID:25068794 |
|
NCBI chr 2:72,766,774...72,810,790
Ensembl chr 2:72,766,771...72,810,790
|
|
G |
Spon2 |
spondin 2, extracellular matrix protein |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPON2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:33,370,862...33,375,596
Ensembl chr 5:33,355,528...33,375,799
|
|
G |
Sprr2g |
small proline-rich protein 2G |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SPRR2G mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 3:92,281,222...92,282,536
Ensembl chr 3:92,281,222...92,282,536
|
|
G |
Spsb4 |
splA/ryanodine receptor domain and SOCS box containing 4 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPSB4 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SPSB4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:96,825,535...96,900,408
Ensembl chr 9:96,825,535...96,900,896
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [ATG7 protein results in decreased expression of SQSTM1 protein] [methylmercuric chloride co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased expression of SQSTM1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [SQSTM1 protein affects the susceptibility to methylmercuric chloride]; methylmercuric chloride promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SQSTM1 mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SQSTM1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SQSTM1 protein |
CTD |
PMID:27629431 PMID:37258240 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [SRC protein binds to NR1I3 protein] |
CTD |
PMID:24224465 PMID:27794399 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Srl |
sarcalumenin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SRL mRNA |
CTD |
PMID:25566086 |
|
NCBI chr16:4,294,843...4,359,772
Ensembl chr16:4,298,080...4,359,680
|
|
G |
Srsf2 |
serine and arginine-rich splicing factor 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [KAT5 protein results in increased acetylation of and results in increased degradation of SRSF2 protein] |
CTD |
PMID:21157427 |
|
NCBI chr11:116,740,723...116,744,511
Ensembl chr11:116,740,727...116,743,920
|
|
G |
Srxn1 |
sulfiredoxin 1 homolog (S. cerevisiae) |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SRXN1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 2:151,946,738...151,953,296
Ensembl chr 2:151,947,436...151,953,296
|
|
G |
Sry |
sex determining region of Chr Y |
decreases degradation multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SRY protein mutant form [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of SRY protein mutant form] which results in increased expression of SOX9 mRNA; SRY protein mutant form promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SRY protein modified form] |
CTD |
PMID:27576690 |
|
NCBI chr Y:2,662,471...2,663,658
Ensembl chr Y:2,662,471...2,663,658
|
|
G |
Sspn |
sarcospan |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SSPN mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of SSPN mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:145,860,423...145,910,951
Ensembl chr 6:145,877,367...145,910,949
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of and results in increased phosphorylation of STAT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tretinoin results in increased expression of STAT1 mRNA] |
CTD |
PMID:20945414 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
affects phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the phosphorylation of STAT6 protein |
CTD |
PMID:12459556 |
|
NCBI chr10:127,478,855...127,496,856
Ensembl chr10:127,478,855...127,496,826
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one inhibits the reaction [STK11 mutant form results in increased expression of MYC protein]] |
CTD |
PMID:24793789 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Strip2 |
striatin interacting protein 2 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of STRIP2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:29,916,975...29,959,680
Ensembl chr 6:29,917,011...29,959,680
|
|
G |
Sts |
steroid sulfatase |
decreases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of STS mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 PMID:24055520 |
|
NCBI chr X:168,856,332...169,015,037
Ensembl chr X:168,909,030...169,014,924
|
|
G |
Suv39h1 |
suppressor of variegation 3-9 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; [TNF protein co-treated with 6-formylindolo(3,2-b)carbazole co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; AHR protein affects the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with alpinetin] results in decreased expression of SUV39H1 protein] |
CTD |
PMID:31676321 |
|
NCBI chr X:7,927,401...7,940,994
Ensembl chr X:7,927,410...7,940,999
|
|
G |
Swt1 |
SWT1 RNA endoribonuclease homolog (S. cerevisiae) |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of SWT1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:151,243,449...151,304,248
Ensembl chr 1:151,243,450...151,304,206
|
|
G |
Sybu |
syntabulin (syntaxin-interacting) |
multiple interactions increases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of SYBU mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr15:44,535,252...44,651,466
Ensembl chr15:44,535,252...44,651,459
|
|
G |
Synpo |
synaptopodin |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of SYNPO mRNA |
CTD |
PMID:25566086 |
|
NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AGT protein results in increased degradation of SYP protein] |
CTD |
PMID:18487452 |
|
NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495
|
|
G |
Taf1 |
TATA-box binding protein associated factor 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of TAF1 protein] |
CTD |
PMID:17409431 |
|
NCBI chr X:100,576,335...100,644,635
Ensembl chr X:100,576,279...100,644,640
|
|
G |
Taf1a |
TATA-box binding protein associated factor, RNA polymerase I, A |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TAF1A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:183,170,251...183,195,776
Ensembl chr 1:183,170,325...183,191,020
|
|
G |
Tardbp |
TAR DNA binding protein |
affects localization increases ubiquitination |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the localization of TARDBP protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of TARDBP protein |
CTD |
PMID:19765185 PMID:31780563 |
|
NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476
|
|
G |
Tdrp |
testis development related protein |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TDRP mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 8:14,002,008...14,025,484
Ensembl chr 8:14,002,008...14,025,032
|
|
G |
Tenm4 |
teneurin transmembrane protein 4 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TENM4 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TENM4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:95,550,262...96,560,300
Ensembl chr 7:95,820,453...96,560,300
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [APP protein modified form results in decreased expression of and results in decreased activity of TERT protein] |
CTD |
PMID:21520056 |
|
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Tesc |
tescalcin |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TESC mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 5:118,165,808...118,199,943
Ensembl chr 5:118,165,808...118,199,943
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [troglitazone results in decreased expression of TFAM mRNA] |
CTD |
PMID:20860658 |
|
NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TFRC mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TFRC mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tg |
thyroglobulin |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Amiodarone results in decreased expression of TG protein] |
CTD |
PMID:25295624 |
|
NCBI chr15:66,542,606...66,722,570
Ensembl chr15:66,542,602...66,722,570
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TGFB1 protein results in decreased expression of LPIN1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TH5487 inhibits the reaction [TGFB1 protein results in increased expression of OGG1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [TGFB1 protein results in increased expression of OGG1 protein] |
CTD |
PMID:27345520 PMID:35654123 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tgfbi |
transforming growth factor, beta induced |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TGFBI mRNA |
CTD |
PMID:25566086 |
|
NCBI chr13:56,757,399...56,787,172
Ensembl chr13:56,757,336...56,787,375
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor I |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR1 protein] |
CTD |
PMID:31381904 |
|
NCBI chr 4:47,353,258...47,414,926
Ensembl chr 4:47,353,222...47,414,931
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of THY1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of THY1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA] |
CTD |
PMID:12147270 |
|
NCBI chr 3:65,435,868...65,462,939
Ensembl chr 3:65,435,831...65,462,939
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TK1 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TK1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918
|
|
G |
Tmem176a |
transmembrane protein 176A |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176A mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:48,818,417...48,822,298
Ensembl chr 6:48,817,853...48,824,005
|
|
G |
Tmem176b |
transmembrane protein 176B |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TMEM176B mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:48,810,745...48,818,363
Ensembl chr 6:48,810,752...48,818,430
|
|
G |
Tmem204 |
transmembrane protein 204 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMEM204 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMEM204 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr17:25,276,676...25,300,088
Ensembl chr17:25,276,676...25,302,565
|
|
G |
Tmod1 |
tropomodulin 1 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMOD1 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMOD1 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:46,038,940...46,116,032
Ensembl chr 4:46,038,935...46,116,032
|
|
G |
Tmt1a |
thiol methyltransferase 1A1 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TMT1A mRNA |
CTD |
PMID:31806706 |
|
NCBI chr15:100,201,969...100,227,882
Ensembl chr15:100,202,021...100,226,543
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases expression |
ISO EXP |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with TNF protein] results in increased phosphorylation of NFKBIA protein; [TNF protein co-treated with 6-formylindolo(3,2-b)carbazole co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; AHR protein affects the reaction [[TNF protein co-treated with alpinetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with alpinetin] results in decreased expression of SUV39H1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [hydroquinone results in increased expression of TNF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of PTGS2 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of VEGFA protein]; TNF protein affects the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Thiopental] affects the phosphorylation of NFKBIA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Zymosan results in increased expression of TNF mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Diclofenac promotes the reaction [[TNF protein co-treated with IL1B protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNF mRNA MG132 pretreatment decreases expression of TNFa, IL6 protein in serum of intestinal ischemia/reperfusion rats |
CTD RGD |
PMID:11230753 PMID:11698246 PMID:12185005 PMID:12628480 PMID:12883408 PMID:14572618 PMID:19393675 PMID:23288922 PMID:23395999 PMID:24085292 PMID:24613819 PMID:28134560 PMID:31676321 PMID:31806706 PMID:22079846 More...
|
RGD:401794136 |
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip1 |
tumor necrosis factor, alpha-induced protein 1 (endothelial) |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNFAIP1 protein results in increased degradation of CSNK2B protein] |
CTD |
PMID:37302538 |
|
NCBI chr11:78,413,676...78,427,122
Ensembl chr11:78,413,676...78,427,158
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [RNF31 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNFAIP3 protein]] |
CTD |
PMID:34416243 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tnfaip8l1 |
tumor necrosis factor, alpha-induced protein 8-like 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNFAIP8L1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr17:56,469,439...56,491,249
Ensembl chr17:56,469,477...56,480,955
|
|
G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TNFRSF10A protein |
CTD |
PMID:16287099 |
|
NCBI chr14:70,004,921...70,021,860
Ensembl chr14:70,004,921...70,021,860
|
|
G |
Tnni1 |
troponin I, skeletal, slow 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 1:135,709,252...135,738,727
Ensembl chr 1:135,707,172...135,738,727
|
|
G |
Tnni2 |
troponin I, skeletal, fast 2 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI2 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI2 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 7:141,995,553...141,998,147
Ensembl chr 7:141,995,545...141,998,147
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
multiple interactions decreases expression |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Doxorubicin results in decreased expression of TNNI3 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TNNI3 mRNA |
CTD |
PMID:19801490 PMID:25566086 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]] |
CTD |
PMID:17575151 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Traf2 |
TNF receptor-associated factor 2 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TRAF2 protein results in decreased expression of KLF2 protein] |
CTD |
PMID:35635602 |
|
NCBI chr 2:25,407,994...25,436,952
Ensembl chr 2:25,407,994...25,436,952
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of TRIB2 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIB3 mRNA |
CTD |
PMID:31806706 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Tril |
TLR4 interactor with leucine-rich repeats |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIL mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIL mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 6:53,792,453...53,797,810
Ensembl chr 6:53,792,453...53,797,815
|
|
G |
Trim72 |
tripartite motif-containing 72 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TRIM72 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:127,602,684...127,610,565
Ensembl chr 7:127,603,121...127,610,205
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases expression increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Zinc Sulfate co-treated with prolinedithiocarbamate] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Capsaicin results in increased degradation of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of TP53 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TP53 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TP53 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Acetaminophen results in increased degradation of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased phosphorylation of and results in increased expression of TP53 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of TP53 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TP53 protein modified form |
CTD |
PMID:10837373 PMID:16330492 PMID:18463101 PMID:18951928 PMID:19699254 PMID:20530418 PMID:21454520 PMID:26612707 PMID:27129209 PMID:27993609 PMID:31806706 PMID:35821281 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp63 |
transformation related protein 63 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cisplatin promotes the reaction [RELA protein binds to TP63 protein alternative form]] which results in increased degradation of TP63 protein alternative form] |
CTD |
PMID:21088498 |
|
NCBI chr16:25,502,513...25,710,842
Ensembl chr16:25,502,513...25,710,852
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP8 protein] inhibits the reaction [Dexamethasone results in increased expression of TSC22D3 protein]] |
CTD |
PMID:20671745 |
|
NCBI chr X:139,440,277...139,501,257
Ensembl chr X:139,440,277...139,501,408
|
|
G |
Tsc22d4 |
Tsc22 domain family, member 4 |
decreases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TSC22D4 mRNA MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of TSC22D4 mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 5:137,744,274...137,758,011
Ensembl chr 5:137,743,992...137,766,712
|
|
G |
Txnl1 |
thioredoxin-like 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [arsenite results in increased degradation of TXNL1 protein] |
CTD |
PMID:19349280 |
|
NCBI chr18:63,795,872...63,825,535
Ensembl chr18:63,794,165...63,841,872
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of TXNRD1 mRNA |
CTD |
PMID:18550526 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Tymp |
thymidine phosphorylase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]] |
CTD |
PMID:21444628 PMID:30796972 |
|
NCBI chr15:89,255,834...89,261,282
Ensembl chr15:89,256,134...89,261,242
|
|
G |
Tyms |
thymidylate synthase |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Fluorouracil co-treated with Cisplatin] results in decreased stability of TYMS protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [cinobufagin results in decreased expression of TYMS protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [trichostatin A results in decreased expression of TYMS protein] |
CTD |
PMID:17172411 PMID:21444628 PMID:35427566 |
|
NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Fenofibrate results in decreased expression of TYR protein] |
CTD |
PMID:23872139 |
|
NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
|
|
G |
Ubb |
ubiquitin B |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[PARK protein co-treated with UBB protein] results in decreased expression of FIS1 protein] |
CTD |
PMID:20164189 |
|
NCBI chr11:62,442,329...62,444,037
Ensembl chr11:62,441,997...62,444,039
|
|
G |
Ubc |
ubiquitin C |
multiple interactions increases expression |
ISO EXP |
HSF1 promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UBC mRNA] |
CTD |
PMID:30186748 |
|
NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UBE2C mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:164,611,849...164,614,822
Ensembl chr 2:164,611,818...164,620,742
|
|
G |
Ube2t |
ubiquitin-conjugating enzyme E2T |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UBE2T mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 1:134,890,303...134,901,918
Ensembl chr 1:134,890,303...134,901,900
|
|
G |
Ubqln1 |
ubiquilin 1 |
increases stability |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased stability of UBQLN1 protein mutant form |
CTD |
PMID:24747970 |
|
NCBI chr13:58,323,970...58,363,467
Ensembl chr13:58,323,970...58,363,467
|
|
G |
Ubr1 |
ubiquitin protein ligase E3 component n-recognin 1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UBR1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 2:120,690,753...120,801,246
Ensembl chr 2:120,690,750...120,801,196
|
|
G |
Ubxn1 |
UBX domain protein 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [NGLY1 protein binds to UBXN1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr19:8,848,912...8,853,030
Ensembl chr19:8,848,860...8,853,227
|
|
G |
Uchl1 |
ubiquitin carboxy-terminal hydrolase L1 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UCHL1 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577
|
|
G |
Ufd1 |
ubiquitin recognition factor in ER-associated degradation 1 |
increases expression multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of UFD1 mRNA [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in increased expression of UFD1 mRNA |
CTD |
PMID:20061341 PMID:25566086 |
|
NCBI chr16:18,630,486...18,654,011
Ensembl chr16:18,630,529...18,654,011
|
|
G |
Uhrf1 |
ubiquitin-like, containing PHD and RING finger domains, 1 |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UHRF1 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr17:56,610,405...56,630,486
Ensembl chr17:56,610,321...56,630,486
|
|
G |
Ulk1 |
unc-51 like kinase 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963
|
|
G |
Unc13c |
unc-13 homolog C |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of UNC13C mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 9:73,386,704...73,915,421
Ensembl chr 9:73,386,704...73,876,248
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of USP14 mRNA |
CTD |
PMID:20061341 |
|
NCBI chr18:9,993,615...10,030,149
Ensembl chr18:9,993,066...10,045,119
|
|
G |
Usp15 |
ubiquitin specific peptidase 15 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [NFE2L2 protein inhibits the reaction [Streptozocin results in increased expression of USP15 protein]] |
CTD |
PMID:35478295 |
|
NCBI chr10:122,940,911...123,032,924
Ensembl chr10:122,940,911...123,032,900
|
|
G |
Usp28 |
ubiquitin specific peptidase 28 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [nickel sulfate results in decreased expression of USP28 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Oxygen deficiency results in decreased expression of USP28 protein] |
CTD |
PMID:20046830 |
|
NCBI chr 9:48,896,577...48,953,817
Ensembl chr 9:48,896,675...48,953,817
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
multiple interactions |
ISO |
[USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; [USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein; Arsenic inhibits the reaction [[USP7 protein mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [[USP7 protein co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of HMOX1 protein]; Arsenic promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [USP7 protein affects the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Wortmannin inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HMOX1 protein binds to USP7 protein]; USP7 protein affects the reaction [Arsenic inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein]]; USP7 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of HMOX1 protein] |
CTD |
PMID:32802178 PMID:35821281 |
|
NCBI chr16:8,506,586...8,574,931
Ensembl chr16:8,507,459...8,610,172
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of VCAM1 mRNA |
CTD |
PMID:11698246 PMID:18457675 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
G |
Vcp |
valosin containing protein |
increases expression multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of VCP protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VCP protein binds to UBXN1 protein binds to PSMD4 protein] |
CTD |
PMID:15362974 |
|
NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [methylmercuric chloride results in decreased expression of VEGFA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Methylmercury Compounds results in decreased expression of VEGFA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of VEGFA mRNA] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in decreased expression of VEGFA mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in decreased expression of VEGFA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [TNF protein results in increased secretion of VEGFA protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of VEGFA protein |
CTD |
PMID:12590138 PMID:24613819 PMID:28651835 PMID:31850806 PMID:32461003 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
multiple interactions |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [VHL protein binds to HIF1A protein]; manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Ketoglutaric Acids co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]]; Quercetin inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [HIF1A protein binds to VHL protein]] |
CTD |
PMID:17973296 PMID:19263519 |
|
NCBI chr 6:113,600,955...113,608,595
Ensembl chr 6:113,600,920...113,608,594
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [AHR protein results in decreased expression of VIM protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [AHR protein binds to VIM protein] |
CTD |
PMID:27752740 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Vwf |
Von Willebrand factor |
decreases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of VWF mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of WWTR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tcdA protein, Clostridium difficile results in decreased expression of WWTR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [toxB protein, Clostridium difficile results in decreased expression of WWTR1 protein] |
CTD |
PMID:33251692 PMID:33539684 |
|
NCBI chr 3:57,363,065...57,483,331
Ensembl chr 3:57,363,070...57,483,331
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases response to substance multiple interactions increases expression |
ISO |
XBP1 protein results in decreased susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of XBP1 protein alternative form]; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of EIF2S1 protein]; [XBP1 mutant form co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] promotes the reaction [Tobacco Smoke Pollution analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:19135031 PMID:25568320 PMID:27638906 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions increases cleavage increases ubiquitination |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[pifithrin co-treated with Topotecan] results in increased degradation of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol results in decreased expression of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [diallyl trisulfide results in decreased expression of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cannabidiol results in increased ubiquitination of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [trimethyltin chloride results in decreased expression of XIAP protein]; Cannabidiol promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of XIAP protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of XIAP protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased cleavage of XIAP protein |
CTD |
PMID:16287099 PMID:19812371 PMID:21411500 PMID:22627131 PMID:23423712 PMID:31699976 More...
|
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Xpc |
xeroderma pigmentosum, complementation group C |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in decreased expression of XPC protein] |
CTD |
PMID:28237621 |
|
NCBI chr 6:91,466,287...91,492,870
Ensembl chr 6:91,466,287...91,492,870
|
|
G |
Yap1 |
yes-associated protein 1 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tcdA protein, Clostridium difficile results in decreased expression of YAP1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [toxB protein, Clostridium difficile results in decreased expression of YAP1 protein] |
CTD |
PMID:33251692 |
|
NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597
|
|
G |
Zbtb8b |
zinc finger and BTB domain containing 8b |
multiple interactions decreases expression |
EXP |
MYBPC3 protein affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ZBTB8B mRNA] |
CTD |
PMID:25566086 |
|
NCBI chr 4:129,320,063...129,340,761
Ensembl chr 4:129,319,558...129,334,646
|
|
G |
Zfand2a |
zinc finger, AN1-type domain 2A |
increases expression |
EXP ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ZFAND2A mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ZFAND2A protein |
CTD |
PMID:24619424 PMID:25566086 PMID:31540997 |
|
NCBI chr 5:139,456,971...139,470,246
Ensembl chr 5:139,456,966...139,470,304
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [hydroquinone results in decreased expression of ZFP36 protein] |
CTD |
PMID:23288922 |
|
NCBI chr 7:28,076,208...28,078,680
Ensembl chr 7:28,076,209...28,079,678
|
|
G |
Zfp941 |
zinc finger protein 941 |
increases expression |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ZFP941 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr 7:140,387,366...140,402,114
Ensembl chr 7:140,387,362...140,402,091
|
|
G |
Zfyve21 |
zinc finger, FYVE domain containing 21 |
multiple interactions |
EXP |
[MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of ZFYVE21 mRNA |
CTD |
PMID:25566086 |
|
NCBI chr12:111,780,600...111,794,822
Ensembl chr12:111,780,604...111,798,626
|
|